

## Emergence and dynamics of delusions and hallucinations across stages in early psychosis

Catalina Mourgues-Codern, Ph.D.<sup>1†</sup>, David Benrimoh, M.D.C.M.<sup>2,3†</sup>, Jay Gandhi, B.A.<sup>1</sup>, Emily A. Farina, Ph.D.<sup>1</sup>, Raina Vin, B.S.<sup>1</sup>, Tihare Zamorano, B.A.<sup>2</sup>, Deven Parekh, M.Sc.<sup>2</sup>, Ashok Malla, M.D.<sup>2</sup>, Ridha Joober, M.D.<sup>2</sup>, Martin Lepage, Ph.D.<sup>2</sup>, Srividya N. Iyer, Ph.D.<sup>2</sup>, Jean Addington, Ph.D.<sup>4</sup>, Carrie E. Bearden, Ph.D.<sup>5</sup>, Kristin S. Cadenhead, M.D.<sup>6</sup>, Barbara Cornblatt, Ph.D.<sup>7</sup>, Matcheri Keshavan, M.D.<sup>8</sup>, William S. Stone, Ph.D.<sup>8</sup>, Daniel H. Mathalon, M.D., Ph.D.<sup>9</sup>, Diana O. Perkins, M.D., M.P.H.<sup>10</sup>, Elaine F. Walker, Ph.D.<sup>11</sup>, Tyrone D. Cannon, Ph.D.<sup>1,12</sup>, Scott W. Woods, M.D.<sup>1,13</sup>, Jai L. Shah, M.D.<sup>2</sup>, Albert R. Powers, M.D., Ph.D.<sup>1,10,12\*</sup>

1. Yale University School of Medicine and the Connecticut Mental Health Center, New Haven, CT, USA
2. McGill University, Montreal, Quebec, Canada
3. Stanford University School of Medicine, Palo Alto, CA, USA
4. University of Calgary, Calgary, Canada
5. University of California Los Angeles, Los Angeles, CA, USA
6. University of California San Diego, La Jolla, CA, USA
7. Hofstra Northwell School of Medicine, Uniondale, NY, USA
8. Beth Israel Deaconess Medical Center, Boston, Harvard Medical School, MA, USA
9. University of California San Francisco, San Francisco, CA, USA
10. University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11. Emory University, Atlanta, GA, USA
12. Yale University Department of Psychology, New Haven, CT, USA
13. Connecticut Mental Health Center, New Haven, CT, USA

\*Correspondence should be addressed to:

Albert R. Powers, M.D., Ph.D.  
The Connecticut Mental Health Center, Rm. S109  
34 Park Street  
New Haven, CT 06519  
[albert.powers@yale.edu](mailto:albert.powers@yale.edu)  
203.974.7329

†Contributed equally

**Running Title:** Delusions precede hallucinations across stages of early psychosis

**Keywords:** Hallucinations, delusions, clinical high-risk, prodrome, first episode psychosis

**Words in main body of manuscript:** 2951

## Abstract

Hallucinations and delusions are often grouped together within the positive symptoms of psychosis. However, recent evidence suggests they may be driven by distinct computational and neural mechanisms. Examining the time course of their emergence may provide insights into the relationship between these underlying mechanisms.

Participants from the second (N = 719) and third (N = 699) iterations of the North American Prodrome Longitudinal Study (NAPLS 2 and 3) were assessed for timing of CHR-P-level delusion and hallucination onset. Pre-onset symptom patterns in first-episode psychosis patients (FEP) from the Prevention and Early Intervention Program for Psychosis (PEPP-Montréal; N = 694) were also assessed. Symptom onset was determined at baseline assessment and the evolution of symptom patterns examined over 24 months.

In all three samples, participants were more likely to report the onset of delusion-spectrum symptoms prior to hallucination-spectrum symptoms (odds ratios (OR): NAPLS 2 = 4.09; NAPLS 3 = 4.14; PEPP,  $Z = 7.01$ ,  $P < 0.001$ ) and to present with only delusions compared to only hallucinations (OR: NAPLS 2 = 5.6; NAPLS 3 = 11.11; PEPP = 42.75). Re-emergence of delusions after remission was also more common than re-emergence of hallucinations ( $P$ s < 0.05), and hallucinations more often resolved first ( $P$ s < 0.001). In both CHR-P samples, ratings of delusional ideation fell with the onset of hallucinations ( $P = 0.007$ ).

Delusions tend to emerge before hallucinations and may play a role in their development. Further work should examine the relationship between the mechanisms driving these symptoms and its utility for diagnosis and treatment.

## Introduction

Hallucinations and delusions frequently co-occur in psychotic illness.<sup>1–5</sup> Since they were first described, these two symptoms have been grouped together into what are now known as the positive symptoms of psychosis.<sup>6,7</sup> However, emerging evidence suggests that delusions and hallucinations may be driven by distinct but related alterations in learning and inference.<sup>8–13</sup> Understanding the dynamic interrelationships between these symptoms could allow for a more nuanced understanding of the distinct mechanisms driving their emergence.

Historically, delusions have been characterized as either primary (e.g. emerging out of delusional mood, a state in which the environment seems to have changed in some unexplainable and potentially aversive way) or as secondary to some other phenomenon (e.g. a delusion arising out of a mood state or perceptual experience).<sup>14</sup> Broadly, cognitive models of psychosis describe delusion formation as the result of an individual's drive to make sense of a confusing or stressful experience.<sup>15–18</sup> One such model, the anomalous experience hypothesis, predicts that delusion formation is a response to unusual perceptual experiences or hallucinations and thus represents a (secondary) attempt by the individual to explain or understand their unusual perceptual experience.<sup>19</sup> In this view, delusions may be the product of normal reasoning processes used to explain confusing or potentially distressing experiences: a patient who hears a voice saying "Join the FBI" multiple times per day may be more likely to conclude and subsequently believe that the FBI is following her. While data exist that support this hypothesis and cognitive models of psychotic symptoms broadly,<sup>3,20–27</sup> these studies are somewhat limited by general-population sampling and cross-sectional designs.

Indirect evidence from the putatively prodromal Clinical High-Risk state for psychosis (CHR-P) indicates that hallucinations and delusions may not emerge at the same time: they co-occur much more frequently after the onset of threshold-level psychosis.<sup>1,2,5</sup> Additionally, delusional ideation is present in nearly all participants with perceptual abnormalities, but perceptual abnormalities are present in only some individuals with delusional ideation.<sup>5,28</sup> However, no known studies have directly examined the relative timing of symptom onset during and directly following symptom emergence. Ideally, longitudinal data would be obtained from large, naturalistically followed samples of individuals when positive symptoms are actively and acutely emerging. Doing so would allow for a more detailed and accurate understanding of symptom emergence and evolution within the natural history of psychosis.

We examined the onset and evolution of delusions and hallucinations over time in two large prospective CHR-P cohorts (N = 719 and 699) and one large retrospective (follow-back) first episode psychosis (FEP) cohort (N = 694). We investigated these questions across stages of illness in order to identify consistencies that may be present before and after psychosis onset.

## Methods

### *Participant groups*

All participants provided written informed consent after receiving a complete description of the constituent studies, which were approved by local ethics committees. This study included three main data sources: CHR-P participants recruited through the second and third waves of the multi-site North American Prodrome Longitudinal Study (NAPLS 2 and 3)<sup>29,30</sup> and an FEP sample from the Prevention and Early Intervention Program for Psychosis (PEPP-Montréal),<sup>31</sup> a Canadian

specialized early intervention service. Further sample characteristics may be found in the Supplemental Materials.

NAPLS participants who met criteria for Attenuated Positive Symptom Syndrome (APSS) with CHR-P-level (scores 3-5) on delusional ideation (i.e., SOPS items P1 Unusual Thought Content or P2 Suspiciousness or Persecutory Ideas) and/or hallucinations (SOPS item P4 Perceptual abnormalities and Hallucinations) were included. The final CHR-P samples included 719 participants from NAPLS 2 and 699 from NAPLS 3.

The PEPP sample consisted of 694 consecutive patients in their first episode of psychosis who were deemed eligible and consented to participate. For eligibility, participants were required not to have taken antipsychotic medication for greater than 30 days prior to referral. Patients with IQ < 70, psychotic illness solely related to substance use, or non-psychiatric causes of mental disorder were not enrolled in PEPP.

### *Measures*

#### *NAPLS 2 and 3*

The Structured Interview for Psychosis-Risk Syndromes (SIPS)<sup>34</sup> was administered to evaluate for a psychosis-risk syndrome by certified personnel at each site. For the purposes of brevity in this paper, we will discuss hallucination- and delusion-spectrum symptoms (e.g. attenuated psychotic symptoms) as hallucinations and delusions, respectively. As has been done previously,<sup>20</sup> CHR-P-level P1 (unusual thoughts) and P2 (suspiciousness) ratings (3-5) were taken as signifying the presence of early delusional ideation. P1 and P2 intensity has been shown to predict delusion formation<sup>20</sup> and progression of illness to psychosis.<sup>28,35,36</sup> CHR-P-level P4 (perceptual abnormalities) ratings (3-5) were taken as ratings of early hallucinatory phenomena. The maximum score for either P1 or P2 was used for subsequent analyses. Based on these ratings, participants were characterized as having only delusions, only hallucinations, both, or neither at each timepoint. Because the SIPS also elicits information on the timing of symptoms onset prior to baseline assessment, we were able to obtain information on the relative timing of onset of hallucinations and delusions even in those who presented with both symptoms at baseline. If the difference between the onset times of delusions and hallucinations was less than one month, we considered the participant to be in the combined-onset group. To further delineate participant trajectories, we identified those participants who ultimately entered remission from those who did not; participants with scores lower than 3 in P1, P2, and P4 during their last available visit were classified as remitters.

#### *PEPP*

Patients in the PEPP sample were assessed at baseline using the Circumstances of Onset and Relapse Schedule (CORS)<sup>37</sup>, which allowed for retrospective determination of pre-onset (prodromal) and initial psychotic symptoms (the *first* prodromal symptom contiguous with psychosis onset), the *first* psychotic symptom, and the *first* psychotic symptom lasting longer than one week). For this analysis, and similar to CHR-P samples, CORS symptoms related to altered beliefs (odd beliefs, delusions, paranoia/suspiciousness) were considered on the delusion spectrum; altered perceptions and hallucinations were considered on the hallucination spectrum. In addition to the retrospective symptom reports, patients were prospectively assessed for psychotic symptoms using the Scale for the Assessment of Positive Symptoms (SAPS)<sup>38</sup> at intake and then at months 1, 2, 3, 6, 9, 12, 18 and 24, for a total of 12 timepoints. For the purposes of this study, the presence or absence of hallucinations and delusions in the prospective sample was established using SAPS questions 7 (global assessment of hallucinations) and 20 (global

assessment of delusions); scores of 0 (none) and 1 (questionable) were coded as 'absent' and scores of 2 (mild) and above were coded as present. As not all subjects had data at each timepoint, analysis at each timepoint was based on the subjects who had provided data at that time.

Further details on measures collected are available in Supplemental Materials.

### *Statistical Analysis*

Different pathways en route to a condition can influence the timing and variability of symptom expression<sup>41</sup>. We sought to determine if hallucinations and delusions exhibited different patterns of variability over time, which could support the possibility of different pathways toward symptom expression. First, we analyzed variability in the severity scores of delusions and hallucinations across subjects over time. The standard deviation of individual symptom scores over time was computed and then compared using a t-test for independent samples (**Fig. 2a,d,g**). Next, we examined variability in the pattern of occurrence of delusions and hallucinations separately over time (regardless of severity) using Lempel-Ziv complexity (LZC)<sup>42</sup>; see Supplemental Materials for details. Because our objective was to compare variability of symptom presence over time, we excluded participants with fewer than 3 timepoints and those who never experienced the symptoms of interest. Mean LZC, computed separately for delusions and hallucinations, was compared using independent-samples t-tests (**Fig. 2b,e,h; Table S23**). Finally, after analyzing variability both in the graded severity and binary pattern of occurrence of each symptom separately, we examined the probability of transitioning between symptom states (having delusions, hallucinations, neither, or both) over time (**Fig. 2c,f,i**). Symptom states were defined by the presence or absence of each individual symptom.

If onset of hallucination emergence is a marker of worsening clinical condition in those who already have delusions, we would expect that delusion severity would also increase along with hallucination onset. Alternatively, if the mechanisms driving hallucinogenesis are a compensatory response to the mechanisms driving delusion formation, we might expect a decrease in delusion severity with hallucination onset. We examined differences in symptom severity across symptom onset timepoints by aligning to hallucination onset and testing for differences across that timepoint using pairwise t-tests.

## **Results**

### ***Delusions emerge before hallucinations in most CHR-P and FEP participants.***

In all samples studied, participants were more likely to present at baseline assessment with only delusions than with only hallucinations (**Fig. 1, Tables S2, S6 and S11**; NAPLS 2: OR = 5.6, CI<sub>95</sub> 3.52 - 7.27; NAPLS 3: OR = 11.11, CI<sub>95</sub>: 6.97 - 17.71; PEPP: OR = 42.75, CI<sub>95</sub>: 18.81 - 97.19). On examination of retrospective reports, delusions also occurred as a first symptom more frequently than hallucinations across all samples (**Fig. 1**, dotted line; NAPLS 2: OR = 4.09, CI<sub>95</sub> 3.20 - 5.23; NAPLS 3 OR = 4.14, CI<sub>95</sub> 3.24-5.28; PEPP Z = 7.01, P < 0.001 (first prodromal symptom) = 4.04, CI<sub>95</sub> 2.77 - 5.90). Elapsed time between first and second symptom onset did not differ significantly between groups (see **Supplemental Results, Table S22**).

### ***Hallucinations are more volatile than delusions in CHR-P.***

As shown in **Figure 1**, participants' symptom profiles evolved in both prospective datasets, with symptoms appearing, resolving, and re-emerging over time (**Tables S18 to S20**). We investigated these patterns in all samples (**Fig. 2**).

We first examined the variance in symptom scores over time for delusions and hallucinations. Hallucinations exhibited a higher mean standard deviation over time than delusions in both CHR-P samples (**Fig. 2a,d**; NAPLS 2:  $T_{718} = 4.836$ , NAPLS 3:  $T_{559} = 3.397$ ,  $P_s < 0.001$ ). Delusions exhibited a higher mean standard deviation over time in the first-episode psychosis sample (**Fig. 2g**; PEPP:  $T_{1069} = 2.884$ ,  $P = 0.004$ ); this may have been influenced by a floor effect in hallucination ratings in this sample (**Fig. S3**).

Next, we examined the complexity of patterns of delusion and hallucination occurrence—how much each symptom appeared and disappeared over time, measured by Lempel-Ziv Complexity (LZC). We found that the LZC of the symptom expression pattern was significantly higher in hallucinations compared to delusions in both CHR-P samples (**Fig. 2b**, NAPLS 2:  $T_{718} = 2.175$ ,  $P = 0.029$ ; **Fig. 2e**, NAPLS 3  $T_{559} = 2.113$ ,  $P = 0.035$ ) but not in the first-episode sample ( $T_{1069} = 0.6118$ ,  $P = 0.0541$ , **Fig. 2h**, **Table S23**).

### ***Hallucinations tend to re-emerge after re-emergence of delusions and resolve more quickly.***

Initial emergence of hallucinations and delusions can only be observed once per participant. However, because participants in all samples were followed over time, it was possible to determine whether patterns of symptom re-emergence across the whole sample recapitulated initial patterns of emergence.

The order of re-emergence and resolution of symptoms over time echoed patterns seen on initial symptom emergence. In all samples' prospective data, participants were more likely to transition from a state of having no symptoms to having delusions alone compared to hallucinations alone (**Fig. 2c**;  $Z_{\text{NAPLS 2}} = 2.2692$ ,  $P = 0.023$ , **Fig. 2f**;  $Z_{\text{NAPLS 3}} = 3.008$ ,  $P = 0.003$ , **Fig. 2i**;  $Z_{\text{PEPP}} = 9.9216$ ,  $P < 0.001$ , **Table 21**). In the opposite direction, hallucination resolution was also more likely than delusion resolution from a state of having both delusions and hallucinations ( $Z_{\text{NAPLS 2}} = 6.7021$ ,  $Z_{\text{NAPLS 3}} = 7.0841$ ,  $Z_{\text{PEPP}} = 5.0529$ ,  $P_s < 0.001$ ).

### ***Delusion severity falls after hallucination onset.***

We next examined the relationship between symptoms at time of initial hallucination onset among CHR-P individuals who developed hallucinations while being followed prospectively (**Fig. 3**).

The initial emergence of hallucinations was found to be preceded by a period of supra-threshold delusion intensity, followed by a decrease in both delusion and hallucination intensity after hallucination onset in both the NAPLS 2 (**Fig. 3a**) and NAPLS 3 (**Fig. 3b**) samples (combined NAPLS 2 and NAPLS 3 samples, pairwise  $T_{43} = 2.831$ ,  $P = 0.007$ ). This pattern was observed in those whose symptoms ultimately remitted ( $T_{15} = 3.727$ ,  $P = 0.002$ ) but not in those whose symptoms persisted or worsened over time ( $T_{24} = .492$ ,  $P = 0.627$ ; **Fig. S1**).

## **Discussion**

Examining the temporal order of psychotic symptom emergence has the potential to deepen our understanding of both phenomenology and the mechanisms driving those symptoms. Consistent patterns of emergence and resolution may help to establish a pathophysiological model for

symptom development within psychosis,<sup>43,44</sup> ultimately shifting the focus of intervention from symptom alleviation to interruption of the pathophysiological processes leading to disease.<sup>45–48</sup>

Across three large samples of individuals in the earliest phases of psychosis, each using retrospective and prospective approaches to symptom measurement, delusions emerge before hallucinations in the majority of those studied. Delusions similarly re-emerge before hallucinations after initial symptoms have remitted, recapitulating the patterns of initial emergence. Hallucinations exhibit a noisier symptom profile, with later emergence and higher symptom volatility over the CHR-P period. Lastly, rather than increasing following hallucination onset, the severity of delusions decreases with hallucination onset in both prospective CHR-P samples. Together, these results provide converging evidence that hallucination emergence may be a secondary (i.e., compensatory) response to the factors driving delusion formation in a majority of individuals in the earliest phases of psychosis.

While perhaps surprising, this possibility is consistent with emerging work in computational psychiatry, which has related the constituent positive symptoms to distinct and opposing alterations in learning and perceptual inference.<sup>10,49,50</sup> Delusions may initially form as the result of inappropriate learning spurred by aberrant bottom-up noise driving experiences of aberrant salience or prediction-error signaling,<sup>27,50–54</sup> whereas hallucinations have consistently been associated with a top-down dominance of expectations (or priors) in perception,<sup>49,55–57</sup> which also tracks with symptom severity over time.<sup>58</sup> Although these mechanisms appear to be in contradiction, we<sup>9</sup> and others<sup>10,59</sup> have proposed that they may simply be separated in time: hallucinations and top-down dominance may be the result of processes attempting to compensate for the pre-existing bottom-up noise that first drives delusion formation. In this rendering, delusions would be expected to emerge before hallucinations in the majority of those studied, as we find here. The unexpected finding that delusion severity falls with hallucination onset is also consistent with this account, potentially reflecting an adaptive downweighting of noisy sensory information or a decrease in delusion-related distress with increased confidence in existing beliefs<sup>60</sup>.

The present findings may also hint at dynamics accompanying transition to a first psychotic episode. Variance in hallucination expression over the CHR-P period is higher than that of delusions. This generally supports the hypothesis that hallucinations are the result of secondary processes: assuming both symptoms are the result of noisy neurobiological processes, the noise inherent in the pathogenesis of two (rather than one) pathophysiological processes may be expected to be additive.<sup>61</sup> It is notable that this difference is not present in the FEP sample, in which we see comparable variability of expression patterns in the two symptoms (**Fig. 2h**). Within our framework, this may denote the development of a steady state between the processes driving delusions and hallucinations, but further work is required to test this idea. Despite these differences, the probabilities associated with symptom emergence, remission, and re-emergence remain the same: delusions emerge and re-emerge before hallucinations. The consistency of this pattern may reflect consistency in the pathophysiological processes driving symptom formation, which is ultimately the result of the ways these underlying processes dynamically interact.

Despite the overall patterns, there is appreciable heterogeneity in symptom onset across all samples. Some individuals develop hallucinations prior to delusions and present for baseline ascertainment with only hallucinations present. As noted in **Tables S1 and S12-14**, these individuals may also exhibit distinct clinical features. Most notably, they are younger and have milder illness and higher functioning. Identification of processes that drive differential patterns of symptom emergence and how they might relate to general factors that influence functioning should be a focus of future work. The observational nature of the PEPP sample limits our ability to evaluate the impact of antipsychotic medications in that data set, and antipsychotics were not a factor in the NAPLS sample by design. The role of medications should also be better delineated in

future work. Therapeutic implications of these findings may extend beyond antipsychotic use: if incoming noise that drives delusion formation is a primary abnormality in most people with psychosis, medications and psychotherapies meant to correct or cope with that abnormality before hallucinogenesis may be particularly promising<sup>62</sup>.

One strength of the current work lies in its use of large samples across the phases of early psychosis. Because there are substantive differences between CHR-P and FEP sample characteristics,<sup>63</sup> convergent evidence is particularly valuable. There are also significant limitations to our efforts. There is inherent difficulty in using broad, clinically-oriented instruments to relate to specific, fine-grained neural processes driving symptom development, despite the repeatedly-demonstrated utility of these instruments for predicting clinical course.<sup>36,64,65</sup> For example, the SOPS P4 item includes low-level perceptual distortions in addition to hallucinations; although this inclusion makes it even more remarkable that we see delusions emerging before hallucinations across samples, more specificity would be desirable. New consensus instruments<sup>66</sup> that separately rate distress, interference, and tenacity ratings could aid future analyses. Ongoing efforts to gather detailed phenotypic and neural data over time as psychosis develops offer an unprecedented opportunity to replicate our findings and test the hypotheses that arise from them.<sup>67</sup>

## References

1. Compton MT, Potts AA, Wan CR, Ionescu DF. Which came first, delusions or hallucinations? An exploration of clinical differences among patients with first-episode psychosis based on patterns of emergence of positive symptoms. *Psychiatry Res.* 2012;200(2-3):702-707.
2. Evensen J, Røssberg JI, Haahr U, et al. Contrasting monosymptomatic patients with hallucinations and delusions in first-episode psychosis patients: a five-year longitudinal follow-up study. *Psychopathology.* 2011;44(2):90-97.
3. Smeets F, Lataster T, Dominguez M de G, et al. Evidence that onset of psychosis in the population reflects early hallucinatory experiences that through environmental risks and affective dysregulation become complicated by delusions. *Schizophr Bull.* 2012;38(3):531-542.
4. López-Silva P, Harrow M, Jobe TH, Tufano M, Harrow H, Rosen C. "Are these my thoughts?": A 20-year prospective study of thought insertion, thought withdrawal, thought broadcasting, and their relationship to auditory verbal hallucinations. *Schizophr Res.* Published online August 6, 2022. doi:10.1016/j.schres.2022.07.005
5. Hermans K, van der Steen Y, Kasanova Z, et al. Temporal dynamics of suspiciousness and hallucinations in clinical high risk and first episode psychosis. *Psychiatry Res.* 2020;290:113039.
6. American Psychiatric Association. *DSM-5 Classification.* American Psychiatric Publishing; 2015.
7. Sadock BJ, Sadock VA, Ruiz P. *Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry.* Lippincott Williams & Wilkins; 2014.
8. Powers AR III, Kelley M, Corlett PR. Hallucinations as top-down effects on perception. *Biol Psychiatry Cogn Neurosci Neuroimaging.* 2016;1(5):393-400.
9. Sheldon AD, Kafadar E, Fisher V, et al. Perceptual pathways to hallucinogenesis. *Schizophr Res.* 2022;245:77-89.
10. Adams RA, Stephan KE, Brown HR, Frith CD, Friston KJ. The Computational Anatomy of Psychosis. *Frontiers in Psychiatry.* 2013;4. doi:10.3389/fpsy.2013.00047
11. Friston KJ. Hallucinations and perceptual inference. *Behavioral and Brain Sciences.* 2005;28(6):764-766. doi:10.1017/s0140525x05290131
12. Teufel C, Subramaniam N, Fletcher PC. The role of priors in Bayesian models of perception. *Frontiers in Computational Neuroscience.* 2013;7. doi:10.3389/fncom.2013.00025
13. Hugdahl K. "Hearing voices": auditory hallucinations as failure of top-down control of bottom-up perceptual processes. *Scand J Psychol.* 2009;50(6):553-560.
14. Kiran C, Chaudhury S. Understanding delusions. *Ind Psychiatry J.* 2009;18(1):3-18.
15. Garety PA, Kuipers E, Fowler D, Freeman D, Bebbington PE. A cognitive model of the positive symptoms of psychosis. *Psychol Med.* 2001;31(2):189-195.

16. Kuipers E, Garety P, Fowler D, Freeman D, Dunn G, Bebbington P. Cognitive, emotional, and social processes in psychosis: refining cognitive behavioral therapy for persistent positive symptoms. *Schizophr Bull.* 2006;32 Suppl 1(Suppl 1):S24-S31.
17. Garety PA, Bebbington P, Fowler D, Freeman D, Kuipers E. Implications for neurobiological research of cognitive models of psychosis: a theoretical paper. *Psychol Med.* 2007;37(10):1377-1391.
18. Maher BA. The relationship between delusions and hallucinations. *Current Psychiatry Reports.* 2006;8(3):179-183. doi:10.1007/s11920-006-0021-3
19. Maher BA. Delusional thinking and perceptual disorder. *J Individ Psychol.* 1974;30(1):98-113.
20. Krabbendam L, Myin-Germeys I, Hanssen M, et al. Hallucinatory experiences and onset of psychotic disorder: evidence that the risk is mediated by delusion formation. *Acta Psychiatr Scand.* 2004;110(4):264-272.
21. Birchwood M, Chadwick P. The omnipotence of voices: testing the validity of a cognitive model. *Psychol Med.* 1997;27(6):1345-1353.
22. Freeman D, Pugh K, Vorontsova N, Antley A, Slater M. Testing the continuum of delusional beliefs: An experimental study using virtual reality. *Journal of Abnormal Psychology.* 2010;119(1):83-92. doi:10.1037/a0017514
23. Escher S, Romme M, Buiks A, Delespaul P, van Os J. Formation of delusional ideation in adolescents hearing voices: a prospective study. *Am J Med Genet.* 2002;114(8):913-920.
24. Hanssen M, Krabbendam L, de Graaf R, Vollebergh W, van Os J. Role of distress in delusion formation. *Br J Psychiatry Suppl.* 2005;48:s55-s58.
25. Bridgwater M, Bachman P, Tervo-Clemmens B, et al. Developmental influences on symptom expression in antipsychotic-naïve first-episode psychosis. *Psychol Med.* 2022;52(9):1698-1709.
26. Smeets F, Lataster T, van Winkel R, de Graaf R, Ten Have M, van Os J. Testing the hypothesis that psychotic illness begins when subthreshold hallucinations combine with delusional ideation. *Acta Psychiatr Scand.* 2013;127(1):34-47.
27. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. *Am J Psychiatry.* 2003;160(1):13-23.
28. Zhang T, Xu L, Tang Y, et al. Isolated hallucination is less predictive than thought disorder in psychosis: Insight from a longitudinal study in a clinical population at high risk for psychosis. *Sci Rep.* 2018;8(1):13962.
29. Addington J, Liu L, Buchy L, et al. North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms. *J Nerv Ment Dis.* 2015;203(5):328-335.
30. Addington J, Liu L, Brummitt K, et al. North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description. *Schizophrenia Research.* 2022;243:262-267. doi:10.1016/j.schres.2020.04.010
31. Shah JL, Crawford A, Mustafa SS, Iyer SN, Joober R, Malla AK. Is the Clinical High-Risk State

a Valid Concept? Retrospective Examination in a First-Episode Psychosis Sample. *Psychiatric Services*. 2017;68(10):1046-1052. doi:10.1176/appi.ps.201600304

32. McGlashan T, Walsh B, Woods S. *The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-Up*. Oxford University Press; 2010.
33. Rosengard RJ, Malla A, Mustafa S, et al. Association of Pre-onset Subthreshold Psychotic Symptoms With Longitudinal Outcomes During Treatment of a First Episode of Psychosis. *JAMA Psychiatry*. Published online 2018. doi:10.1001/jamapsychiatry.2018.2552
34. Miller TJ, McGlashan TH, Woods SW, et al. Symptom assessment in schizophrenic prodromal states. *Psychiatr Q*. 1999;70(4):273-287.
35. Niles HF, Walsh BC, Woods SW, Powers AR 3rd. Does hallucination perceptual modality impact psychosis risk? *Acta Psychiatr Scand*. 2019;140(4):360-370.
36. Cannon TD, Yu C, Addington J, et al. An individualized risk calculator for research in prodromal psychosis. *Am J Psychiatry*. 2016;173(10):980-988.
37. Payne J, Malla A, Norman R, Windell D, Brown N. Status of First-Episode Psychosis Patients Presenting for Routine Care in a Defined Catchment Area. *The Canadian Journal of Psychiatry*. 2006;51(1):42-47. doi:10.1177/070674370605100108
38. Andreasen NC. *Scale for the Assessment of Positive Symptoms: SAPS*.; 1984.
39. Paquin V, Malla AK, Iyer SN, Lepage M, Joober R, Shah JL. Combinations and Temporal Associations Among Precursor Symptoms Before a First Episode of Psychosis. *Schizophr Bull*. Published online October 20, 2023. doi:10.1093/schbul/sbad152
40. Paquin V, Cupo L, Malla AK, Iyer SN, Joober R, Shah JL. Dynamic association of the first identifiable symptom with rapidity of progression to first-episode psychosis. *Psychol Med*. 2023;53(5):2008-2016.
41. Park S, Supek F, Lehner B. Higher order genetic interactions switch cancer genes from two-hit to one-hit drivers. *Nat Commun*. 2021;12(1):7051.
42. Lempel A, Ziv J. On the Complexity of Finite Sequences. *IEEE Trans Inf Theory*. 1976;22(1):75-81.
43. Insel TR, Quirion R. Psychiatry as a clinical neuroscience discipline. *JAMA*. 2005;294(17):2221-2224.
44. Cupo L, McIlwaine SV, Daneault JG, et al. Timing, Distribution, and Relationship Between Nonpsychotic and Subthreshold Psychotic Symptoms Prior to Emergence of a First Episode of Psychosis. *Schizophr Bull*. 2021;47(3):604-614.
45. Frohlich ED. Pathophysiology: Applied Clinical Physiology. *Arch Intern Med*. 06 1977;137(6):723-723.
46. Thorwald J. *The Century of the Surgeon*. New York : Pantheon; 1957.
47. Bliss M. *William Osler: A Life in Medicine*. Oxford University Press; 2007.

48. Bliss M. *The Making of Modern Medicine: Turning Points in the Treatment of Disease*. University of Chicago Press; 2011.
49. Corlett PR, Horga G, Fletcher PC, Alderson-Day B, Schmack K, Powers AR. Hallucinations and Strong Priors. *Trends Cogn Sci*. 2019;23(2). doi:10.1016/j.tics.2018.12.001
50. Sterzer P, Adams RA, Fletcher P, et al. The Predictive Coding Account of Psychosis. *Biol Psychiatry*. 2018;84(9):634-643.
51. Corlett PR, Taylor JR, Wang XJ, Fletcher PC, Krystal JH. Toward a neurobiology of delusions. *Prog Neurobiol*. 2010;92(3):345-369.
52. Corlett PR, Cambridge V, Gardner JM, et al. Ketamine effects on memory reconsolidation favor a learning model of delusions. *PLoS One*. 2013;8(6):e65088.
53. Corlett PR, Fletcher PC. The neurobiology of schizotypy: fronto-striatal prediction error signal correlates with delusion-like beliefs in healthy people. *Neuropsychologia*. 2012;50(14):3612-3620.
54. Menon V, Palaniyappan L, Supekar K. Integrative Brain Network and Salience Models of Psychopathology and Cognitive Dysfunction in Schizophrenia. *Biol Psychiatry*. 2023;94(2):108-120.
55. Powers AR, Mathys C, Corlett PR. Pavlovian conditioning-induced hallucinations result from overweighting of perceptual priors. *Science*. 2017;357(6351):596-600.
56. Cassidy CM, Balsam PD, Weinstein JJ, et al. A Perceptual Inference Mechanism for Hallucinations Linked to Striatal Dopamine. *Curr Biol*. 2018;28(4):503-514 e4.
57. Alderson-Day B, Lima CF, Evans S, et al. Distinct processing of ambiguous speech in people with non-clinical auditory verbal hallucinations. *Brain*. 2017;140:2475-2489.
58. Kafadar E, Fisher VL, Quagan B, et al. Conditioned Hallucinations and Prior Overweighting Are State-Sensitive Markers of Hallucination Susceptibility. *Biol Psychiatry*. 2022;92(10):772-780.
59. Peggy Series. *Computational Psychiatry: A Primer*. MIT Press; 2020.
60. Mishara AL. Klaus Conrad (1905-1961): delusional mood, psychosis, and beginning schizophrenia. *Schizophr Bull*. 2010;36(1):9-13.
61. Rao MM. *Stochastic Processes - Inference Theory*. Springer; 2014.
62. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. *Neuropsychopharmacology*. 2012;37(1):4-15.
63. Hagler MA, Ferrara M, Yoviene Sykes LA, et al. Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis. *Schizophr Res*. 2023;255:239-245.
64. Woods SW, Walsh BC, Addington J, et al. Current status specifiers for patients at clinical high risk for psychosis. *Schizophr Res*. 2014;158:69-75.

65. Woods SW, Powers AR, Taylor JH, et al. Lack of diagnostic pluripotentiality in patients at clinical high risk for psychosis: Specificity of comorbidity persistence and search for pluripotential subgroups. *Schizophr Bull.* 2018;44(2). doi:10.1093/schbul/sbx138
66. Woods SW, Parker S, Kerr MJ, et al. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS. *Early Interv Psychiatry.* Published online August 28, 2023. doi:10.1111/eip.13457
67. Brady LS, Larrauri CA, AMP SCZ Steering Committee. Accelerating Medicines Partnership Schizophrenia (AMP SCZ): developing tools to enable early intervention in the psychosis high risk state. *World Psychiatry.* 2023;22(1):42-43.




## Figure Legends










### **Figure 1. Delusions emerge before hallucinations in most CHR-P and FEP participants.**

Sankey diagrams of prevalence of attenuated psychotic symptoms at emergence, baseline assessment, and follow-up timepoints in NAPLS 2 (**a**, N = 719), NAPLS 3 (**b**, N = 699), and PEPP (**c**, N = 694). Participants were 4.15, 8.52, and 3.36 times more likely to report delusions as a first symptom than hallucinations, respectively. The width of the edges between nodes is proportional to the percentage of participants that transition from one symptom to another. Dotted line on the x axis denotes retrospectively-obtained data. Red = hallucinations; blue = delusions; gray = remission. See Tables S18 - S20 for raw category and transition numbers.


**Figure 2. Delusions are more stable and re-emerge before hallucinations.** Over the time followed, hallucination severity scores (**a,d**) were more variable in the CHR-P samples, and hallucinations were much more likely to be volatile in their expression, appearing and resolving more frequently than delusions, which were more stable (**b,e**). These findings were not present in the FEP sample (**g,h**). However, in all three samples, the probability of transitioning from no CHR-P level symptoms to CHR-P level delusions alone was significantly higher than the probability of transitioning to hallucinations alone (**c,f,i**). Hallucination resolution was also more likely than delusion resolution from a state of having both CHR-P level delusions and hallucinations. Red = hallucinations; blue = delusions; gray = remission; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ . Line shading and error bars = 1 SEM.

**Figure 3. Delusion severity falls after hallucination onset.** In both NAPLS 2 (**a**) and NAPLS 3 (**b**), delusion severity on the SOPS decreased after hallucination onset (time 0). Combined NAPLS 2 and NAPLS 3 samples, pairwise  $T_{43} = 2.831$ ,  $P = 0.007$ . Red = hallucinations; blue = delusions.


**a****NAPLS 2****b****NAPLS 3****c****PEPP**



# NAPLS 2



# NAPLS 3



## Supplementary Information

### Emergence and dynamics of delusions and hallucinations across stages in early psychosis

#### Supplemental Methods

##### *Sample*

CHR-P participants met the Criteria of Psychosis-Risk Syndromes (COPS) based on the Structured Interview for Psychosis-Risk Syndromes (SIPS).<sup>1</sup> FEP participants from PEPP-Montréal<sup>2,3</sup> (hereinafter referred to as PEPP) were admitted to the service for a first episode of affective or non-affective psychosis between 2003 and 2018.

NAPLS 2 was conducted from 2008 to 2013. Participants were between 12 and 35 years old, and 764 met inclusion criteria for CHR-P. NAPLS 3 was conducted from 2014 to 2019. Participants were between 12 and 30 years old, and 710 met diagnostic criteria for a prodromal syndrome rated on the Scale of Prodromal Symptoms (SOPS). See Addington et al. for more details about the study and sample.<sup>4,5</sup> From NAPLS 2, 45 participants were excluded: 25 were below CHR-P level for these symptoms and 20 scored in the psychotic-level range. From the NAPLS 3 sample, 11 were excluded: 6 scored below CHR-level for these symptoms, and 5 scored in the psychotic-level range and were designated as having Brief Intermittent Psychotic Syndrome (BIPS).

The PEPP program is publicly funded and serves a catchment area of ~300,000 people; patients are drawn from multiple referral sources, including self-referral. In the PEPP dataset, patients were between the ages of 14 and 35 at time of referral. The selected sample consisted of 694 patients at baseline. PEPP serves as the sole first episode psychosis service in this area. The overall PEPP study received approval from the Douglas Hospital Research Centre's research ethics board, and participants provided written informed consent to be enrolled in the PEPP cohort. 80.51% of the patients accepted into the PEPP protocol study during this time period accepted to participate in the study.

##### *Measures*

##### *NAPLS 2 and 3*

In both NAPLS 2 and 3, participants were administered various tasks, interviews, and self-report measures. Participants from NAPLS 2 were assessed at baseline and four follow-ups over two years: 6, 12, 18, and 24 months. Participants from NAPLS 3 were also assessed over two years, with more frequent follow-ups: every two months in the first year and then at 18 and 24 months.

The Structured Interview for Psychosis-Risk Syndromes (SIPS)<sup>6</sup> was administered to evaluate for a psychosis-risk syndrome. Presence of CHR-P corresponded to: 1) attenuated positive symptoms (APS) or fully psychotic positive symptoms occurring within a very brief period of time; and/or 2) decline in global functioning with schizotypal personality disorder earlier than age 19; and/or 3) a family history of schizophrenia-spectrum illness accompanied by a decline in functioning. The final sample consisted of only individuals meeting criteria for APS. The SIPS is accompanied by an instrument, the Scale of Prodromal Symptoms (SOPS), which assists in the rating of the severity of relevant symptoms on a 7-

point scale ranging from absent (scores from 0 to 2), moderate to severe but not psychotic (CHR-P level, 3 to 5) and severe and psychotic (score of 6). The SOPS gauges several distinct categories of prodromal symptom domains including positive (unusual thoughts, suspiciousness, grandiosity, perceptual abnormalities, disorganized communication) and negative dimensions (social anhedonia, avolition, expression of emotion, experience of emotions and self, ideational richness, occupational functioning). Ratings of positive symptoms in the range of 3 to 5 are required for designation as being at CHR-P.

As has been done previously,<sup>7</sup> P1 (unusual thoughts) and P2 (suspiciousness) ratings were taken as signifying the presence of early delusional ideation. P1 and P2 intensity has been shown to predict delusion formation<sup>7</sup> and progression of illness to psychosis.<sup>8-10</sup> P4 (perceptual abnormalities) ratings were taken as ratings of early hallucinatory phenomena. The maximum score for either P1 or P2 was used for subsequent analyses. Those with P1 or P2 scores between 3 and 5 at baseline who did not meet criteria for P4 were classified as participants with only delusions. Participants with P4 scores between 3 and 5 at baseline who did not meet criteria on P1 or P2 were categorized as those with only hallucinations. During the analysis, we did not consider grandiose ideas (P3). We made this decision based on the following factors: a) Grandiose ideas occur less frequently than P1 and P2 at baseline (symptoms at baseline in the range of 3 to 5, NAPLS 2, P1 = 82.3%, P2= 67.5%, P3 = 16.3%, NAPLS 3, P1 = 89.99%, P2 = 72.96% and P3 = 17.88%) and they have a significant but not complete overlap with P1, P2, and P4 (96.58% in NAPLS 2 and 71, 35% NAPLS 3, P3 co-occur with P1 or P2, 13.2% in NAPLS 2 and 19.2% in NAPLS 3 co-occur with P4). b) According to factorial analysis, P3 usually loads on a different factor than P1 and P2<sup>11,12</sup>. This indicates that there may be a different delusional process involved in P3 than in P1 and P2. c) Lastly, grandiose ideas have not been found to predict psychosis strongly and are not coded separately in the PEPP sample using the CORS. Participants who had SOPS scores between 3 and 5 on both P4 and either P1 or P2 were categorized as having both delusions and hallucinations. Because the SIPS also elicits information on the timing of onset of symptoms that occurred at (and prior to) the baseline assessment, we were able to obtain information on the relative timing of onset of hallucinations and delusions even in those who presented with both symptoms at baseline. Thus, we were able to identify two additional groups, those who started with hallucinations and then developed delusions and those who developed delusions and then hallucinations. If the difference between the onset times of delusions and hallucinations was less than one month, we considered the participant to be in the combined-onset group. To further delineate participant trajectories, we identified those participants who ultimately entered remission from those who did not; participants with scores lower than 3 in P1, P2, and P4 during their last available visit were classified as remitters.

### *PEPP*

Patients in the PEPP sample were assessed at baseline using the Circumstances of Onset and Relapse Schedule (CORS)<sup>13</sup> which allowed for a retrospective determination of prodromal and initial psychotic symptoms (the *first* prodromal symptom, the *first* psychotic symptom, and the *first* psychotic symptom lasting longer than one week). For this analysis, and similarly to what was done in the CHR-P samples, CORS symptoms related to altered beliefs (odd beliefs, delusions, paranoia) were considered on the delusion spectrum; altered perceptions and hallucinations were considered on the hallucination spectrum. Note that the data available for the retrospective timepoints differs from the data collected at later timepoints: the retrospective data asks about the *first* symptom in a given category, and definitive information about *concurrent* symptoms is not available.

In addition to the 3 retrospective timepoints, patients were prospectively assessed for psychotic symptoms using the Scale for the Assessment of Positive Symptoms (SAPS)<sup>14</sup> at intake and then at months 1, 2, 3, 6, 9, 12, 18, and 24, for a total of 12 timepoints. For the purposes of this study, the presence or absence of hallucinations and delusions in the prospective sample was established using the SAPS questions 7 (global assessment of hallucinations) and 20 (global assessment of delusions); scores of 0 (none) and 1 (questionable) were coded as ‘absent’ and scores of 2 (mild) and above were coded as present. While remission of symptoms on the SAPS is often considered to be present at mild symptoms and below,<sup>15</sup> our choice for binarization was made as we were interested in following subtle changes in symptoms over time that might reflect underlying computational processes. In addition, as this was a treated sample, examining mild symptoms allowed for the assessment of symptoms that were present though symptomatically controlled by medication, which is likely relevant to understanding symptom transitions over time. As not all subjects had data at each point, analysis at each point was based on the subjects who had provided data at that time.

### *Statistical Analysis*

*R studio* (RStudio, PBC, Boston, MA) and Python were used for all statistical analyses and visualizations, utilizing packages *networkD3*, *longCatEDA*, and *Matplotlib*. We constructed a Sankey diagram to depict the flow of patients to and from our established symptom categories over time using group transition frequencies at each timepoint (**Fig. 1**). To aid comparison with the other groups, the Sankey diagram for the PEPP sample (**Fig. 1c**) only included participants with a first reported prodromal symptom of delusions or hallucinations. However, the PEPP sample also included participants with other types of first symptoms (e.g., disorganization or mood related), and these participants were retained for subsequent analyses<sup>16,17</sup>. Proportions of participants reporting symptoms of each category as first symptoms were compared using odds ratios, chi-squared tests, z-tests, and post-hoc tests adjusted for multiple comparisons when applicable. Differences in clinical features were analyzed using ANOVA.

In the NAPLS 2 and 3 samples, the time elapsed between the first and second symptoms was calculated by subtracting the onset dates of the first and second symptoms. The mean onset times per symptom were compared using an independent samples t-test (**Table S22**).

We calculated LZC based on the binary time course of delusion and hallucination presence, considering SIPS or SAPS score > 2, as above. LZC is a measure of variability of a binary sequence; small numbers connote fewer observed patterns, while higher numbers connote greater variability in the observed patterns. The probability of discovering additional patterns in a sample is correlated with the number of measurement points taken. As our samples consist of varying measurement time points, we calculated standardized LZC scores to facilitate easy comparison between samples. Missing data points were not considered as patterns in our analysis.

## **Supplemental Results**

### *Symptom presentation at Baseline*

In NAPLS 2, 95.3% of the participants met the criteria for Attenuated Psychotic Symptoms, while in NAPLS 3, the percentage was 99.4%. The remaining percentages corresponded to Genetic Risk and Functional Decline psychosis-risk syndrome.

In NAPLS 2, for those that presented with delusions only, the onset of hallucinations was, on average, 11.35 months (SD = 5.66, n = 28) after baseline. The onset of delusions for those who presented only hallucinations at baseline was reported on average at 10.33 months (SD = 8.24, n = 12) from baseline. In the NAPLS 3 sample, those who reported only delusions, the onset of hallucinations was reported on average 6.02 months (SD = 5.61, n = 47) after baseline, and for those with only hallucinations, the onset of delusions was reported at an average of 8.71 months (SD = 6.10, n = 7) after baseline. In the PEPP sample, the mean prodrome length was 22.92 months (SD = 38.09, n = 541; **Table S22**).

Across all three samples, mean SOPS scores for hallucinations were lower than those for delusions (**Fig. S3**; NAPLS 2,  $M_{Hall} = 2.56$ ,  $SD_{Hall} = 1.024$ ,  $SEM_{Hall} = 0.063$ ,  $M_{Del} = 3.10$ ,  $SD_{Del} = 0.977$ ,  $SEM_{Del} = 0.05$ ,  $T_{718} = 6.4597$ ,  $P < 0.001$ ; NAPLS 3,  $M_{Hall} = 2.524$ ,  $SD_{Hall} = 1.064$ ,  $SEM_{Hall} = 0.057$ ,  $M_{Del} = 3.01$ ,  $SD_{Del} = 0.967$ ,  $SEM_{Del} = 0.049$ ,  $T_{559} = 6.3997$ ,  $P < 0.001$ ; PEPP,  $M_{Hall} = 1.15$ ,  $SD_{Hall} = 1.08$ ,  $SEM_{Hall} = 0.04$ ,  $M_{Del} = 1.75$ ,  $SD_{Del} = 0.912$ ,  $SEM_{Del} = 0.037$ ,  $T_{1203} = 10.2873$ ,  $P < 0.001$ )

### *Symptom progression*

In NAPLS 2, approximately ~50% of participants reported the same symptoms between two consecutive visits. However, the percentage of participants who reported hallucinations over two consecutive visits was lower than the other symptoms. Once the symptoms disappear, there is a higher likelihood of remaining without symptoms than having a new one on the next visit. Only a small percentage of the symptoms reemerge, with delusions only being the highest proportion of symptoms reappearance, followed by delusions and hallucinations and hallucinations only. Hallucinations were the most frequent symptom before the symptom disappeared. The patterns were similar in NAPLS 3. The highest percentages corresponded to participants who, from one visit to the next one, had the same symptoms. Most participants who reported no symptoms in a visit remained with no symptoms to the next one. Unlike NAPLS 2, in this sample, when the symptoms reemerge, delusions only and hallucinations only proportionally more frequent than hallucinations and delusions. The same was true when participants transitioned from not having symptoms to having new ones (see **Tables S18 to S20** for transition frequencies and conditional probabilities).

In the PEPP sample, patients with neither symptom continue to have no symptoms at the next time point; when symptoms recur, delusions are the most frequent category, followed by delusions and hallucinations, and finally by hallucinations alone. Those with delusions only commonly persist in having delusions at each transition point, with transitions to delusions and hallucinations becoming symptom-free being more likely than transition to hallucinations only. Similarly, those with hallucinations only do not tend to transition to only delusions- but rather to continue having hallucinations (at lower rates than those with delusions continue having delusions only), to switch to hallucinations and delusions, or to become symptom free.

### *Clinical characteristics of symptom groupings*

Clinical characteristics also varied among symptom emergence profiles (**Table S12 to S15**). Participants who presented with only hallucinations at baseline were younger than the other groups (NAPLS 2,  $F_{2, 716} = 11.24$ ,  $p < 0.001$ ; NAPLS 3:  $F_{2, 696} = 17.358$ ,  $p < 0.001$ ), had higher general (Global Assessment of Functioning, GAF; NAPLS 2,  $F_{4, 709} = 3.001$ ,  $P = .018$ ,  $\eta^2 = .017$ ; NAPL 3:  $F_{4, 689} = 4.906$ ,  $P < 0.001$ ,  $\eta^2 = .028$ ) and social functioning (Global Functioning Social Scale (GFS), NAPLS 2:  $F_{4, 705} = 4.102$ ,  $P = 0.002$ ,  $\eta^2 = .023$ ; NAPLS 3:  $F_{4, 692} = 5.987$ ,  $p < 0.001$ ,  $\eta^2 = 0.033$ ) and less severe depressive symptoms (NAPLS 2:  $F_{4, 673} = 5.686$ ,  $P < .001$ ,  $\eta^2 = 0.033$ ; NAPLS 3:  $F_{4, 692} = 3.957$ ,  $P = 0.003$ ,  $\eta^2 = .023$ ). Rates of conversion to psychosis did not differ significantly based on symptom profile, but ORs trended toward a higher chance of conversion for participants with delusions as a first symptom compared with those reporting hallucinations (OR = 2.20) both symptoms (OR = 2.54) at onset (**Table S16 & S17**).

### *Symptom transition probabilities*

To calculate probabilities of transition between states, the number of transitions between states was counted, and then the transition probability for each interval was calculated by dividing the count by the total count of a specific state; finally, the probabilities were averaged, and z-tests for differences between proportions were conducted (**Fig 2c,f,i; Table S18 to S20**).

### *Supplementary Analysis: data from the Topography of Psychotic Episode (TOPE) in the PEPP sample*

Additional evidence of the relative stability of delusions to hallucinations can be found in the data from the Topography of Psychotic Episode (TOPE) assessment collected on a subset ( $n = 434$ ) of the patients in the PEPP sample. In this assessment, the presence or absence of symptoms prior to the prodrome and their course was collected. With respect to course, symptoms were rated as not having been present during the prodrome; having been present during one phase or time period in the prodrome; having been present during several phases or time periods; having been present in a persistent manner during the prodrome; having onset only after psychosis onset; or representing a lifelong pattern of behavior. We note that (expected, given this is a retrospective data about the prodromal phase) a low number of delusion and hallucination symptoms should lead to cautious interpretations of findings from assessment of those symptoms.

Comparing Delusion spectrum symptoms (Odd/bizarre ideas, suspiciousness/ideas of reference, and delusions) to Hallucination spectrum samples (Unusual perceptual experiences, hallucinations), we see several important patterns (Table below). Firstly, it is more common for patients to experience delusion spectrum symptoms than hallucination spectrum symptoms, with more than double the number of patients reporting the most common delusion spectrum symptom (suspiciousness/ideas of reference, 39%) compared to the most common hallucination spectrum symptom (unusual perceptual experiences, 18%). When examining the course of symptoms and ignoring hallucinations and delusions (due to their low incidence), we see that the most persistent symptom is again suspiciousness/ideas of reference, with 21% of patients experiencing this symptom persistently during the prodrome, compared to 7.4% of patients experiencing perceptual alterations in a persistent manner. While this data is limited by its retrospective nature, these results support the finding that delusion-spectrum symptoms are both more common and more persistent in the prodrome.

Finally, while there is significant missing data in the TOPE for onset dates (~20%), we can examine whether patients tended to experience delusion and hallucination symptoms separately at onset, or at the

same time. Of 45 patients for whom onset dates are available for both suspiciousness/ideas of reference and unusual perceptual experiences, 24 (53%) had the same onset date for both. In the 34 patients for whom onset dates were available for both odd/bizarre ideas and unusual perceptual experiences, 15 (44%) had the same onset date for both. In interpreting this one must be wary of recall bias; one might expect dates to be merged in recall when recall of specific symptom onsets were unclear. However, the conclusion can be drawn that these symptoms do not always begin at the same time, and from the results reported in the main paper, delusion-spectrum symptoms tend to be reported first, and they are reported more frequently overall, which again supports the primordial nature of hallucination-like symptoms. This also suggests that a larger proportion of those who had unusual perceptual experiences also had delusion-spectrum symptoms than vice versa: 45 patients have onset dates for both suspiciousness/ideas of reference and unusual perceptual experiences. Therefore at least 45 of 78 patients with unusual perceptual experiences (58%) also experienced suspiciousness; however, that also means at least 45 of 168 patients with suspiciousness (27%) also experienced unusual perceptual experiences. As such, it seems that it was more common to experience suspiciousness in isolation than in combination with perceptual experiences.

## Supplemental Tables

**Table S1. NAPLS 2 and 3 demographic information**

		Age		Sex	Race/ Ethnicity				
		N	Mean	SD	% Male	Hispanic	White	Black	Other
	Hall - Del	80	17.31	3.82	50.00	21.30	61.30	18.80	19.90
	Del - Hall	159	18.59	3.95	58.50	18.90	59.70	17.60	22.70
NAPLS 2	Del & Hall	275	18.61	4.39	54.20	17.50	59.30	4.50	36.20
	Hall	40	15.85	2.83	52.50	12.80	61.50	5.10	33.40
	Del	165	19.28	4.28	61.80	18.80	47.90	18.80	33.30
	Hall - Del	105	17.20	3.49	46.70	20.00	58.10	9.50	32.40
	Del - Hall	154	17.92	4.07	51.90	20.80	48.70	13.00	38.30
NAPLS 3	Del & Hall	240	17.82	3.80	50.80	23.30	57.90	11.30	30.80
	Hall	21	16.52	3.82	61.90	14.30	61.90	14.30	23.80
	Del	179	19.63	4.25	63.10	16.80	56.20	11.20	32.60

Note. Age differences were found in NAPLS 2 and 3 (NAPLS 2,  $F_{(4,714)} = 7.305$ ,  $\eta^2 = .039$ , multiple comparisons: Hall < Del-Hall, Del & Hall and Del, Del > Hall-Del,  $P_s < 0.01$ ; NAPLS 3,  $F_{(4,694)} = 9.273$ ,  $\eta^2 = .051$ ,  $P_s < 0.001$ , multiple comparisons, Del > Del-Hall, Hall- Del, Del & Hall and Hall,  $P_s < 0.01$ ). No association between sex and first symptom was found in NAPLS 2 ( $\chi^2(4) = 4.379$ ,  $P = ns$ ). However, those who presented delusions at first symptom were more likely to be males (Del-Hall:  $Z = 2.141$ ,  $P = 0.032$ , Del:  $Z = 3.036$ ,  $P = 0.002$ ). In NAPLS 3, we did find an association between sex and first symptom ( $\chi^2(4)_{MO} = 10.033$ ,  $P = 0.040$ ) among those whose first symptoms were delusions, males were more predominant ( $Z = 3.513$ ,  $P < 0.001$ ).

**Table S2. NAPLS 2. Frequency and percentage of symptoms reported from baseline to 24 months**

Visit		NS	Del	Hall	Del&Hall	Total	$\chi^2(1)$
BL	Fr	0	165	40	514	719	11.278*
	%	0	22.9	5.6	71.5	100	
M6	Fr	106	135	36	209	486	47.04*
	%	21.6	28	7.4	43	100	
M12	Fr	112	111	35	135	394	34.93*
	%	28.5	28.2	8.9	34.4	100	
M18	Fr	95	80	24	63	262	15.65*
	%	36.3	30.5	9.1	24	100	
M24	Fr	109	67	22	64	262	29.10*
	%	41.6	25.6	8.4	24.4	100	

Note. NS = No symptoms; Del = Only Delusions; Hall = Only Hallucinations; Del&Hall = Delusions and Hallucinations; Fr = Frequency; BL = Baseline; M6 = 6 months; M12 = 12 months; M18 = 18 months; M24 = 24 months. \* $p < 0.001$ . Chi-square as a test of independence was conducted comparing delusions and hallucinations as dichotomous categories. The chi-square of goodness of fit test comparing 3 and 4 categories was significant at each time point  $\chi^2(2)_{BL} = 256.185$ ,  $\chi^2(3)_{6MO} = 71.867$ ,  $\chi^2(3)_{12MO} = 26.159$ ,  $\chi^2(3)_{18MO} = 37.489$ ,  $\chi^2(3)_{24MO} = 32.504$ ,  $ps < 0.001$ ).

**Table S3. NAPLS 2. Frequency of CHR symptoms at each timepoint in participants who converted to psychosis**

	NS	Del	Hall	Del&Hall	Total
BL	0	14	4	55	73
M6	4	9	0	20	33
M12	2	5	0	5	12
M18	3	1	1	2	7
M24	2	0	1	1	4

Note. 73 participants reached a severity score of 6 during the study. On average, participants who converted to psychosis did so 11.32 (SD = 9.27) months after baseline. Of those, 9.2% (6) experienced hallucinations, 47.7% (31) experienced delusions, and 43.1% (28) experienced both at the conversion visit. Participants who converted were 3.5 times more likely to present delusion only than hallucinations only at baseline ( $Z = 2.513$ ,  $P = 0.011$ ), and 13.75 times more likely to have hallucinations and delusions together than only hallucinations at baseline ( $Z = 8.6012$ ,  $P < 0.001$ ).

**Table S4. NAPLS 2. Frequency of CHR symptoms at each timepoint in participants who persisted**

	NS	Del	Hall	Del&Hall	Total
BL	0	67	13	244	324
M6	23	89	22	159	293
M12	18	82	21	116	237
M18	15	68	18	57	158
M24	0	67	21	63	151

Note. Throughout the study, symptoms persisted in 324 participants. The likelihood of having only delusions was 5.15 times greater than that of having only hallucinations ( $Z = 6.4486, P < 0.001$ ). Moreover, this likelihood was markedly higher, at 18.76 times, when compared to the occurrence of both delusions and hallucinations together ( $Z = 18.55, P < 0.001$ ).

**Table S5. NAPLS 2. Frequency of CHR symptoms at each time point in participants who remitted**

	NS	Del	Hall	Del&Hall	Total
BL	0	44	17	110	171
M6	77	38	14	30	159
M12	92	24	14	14	144
M18	77	11	5	4	97
M24	107	0	0	0	107

Note. Throughout the study, symptoms persisted in 171 participants. The likelihood of having only delusions was 2.58 times greater than that of having only hallucinations ( $Z = 3.8138, P < 0.001$ ). Moreover, this likelihood was markedly higher, at 6.47 times, when compared to the occurrence of both delusions and hallucinations together ( $Z = 10.4082, P < 0.001$ ). In the NAPLS 2 study, 26.14% of them (188) were assessed only at the baseline stage. These participants were not included in the symptom persistence or remitter group.

**Table S6. NAPLS 3. Frequency and percentage of symptoms reported from baseline to 24 months**

Visit		NS	Del	Hall	Del&Hall	Total	$\chi^2(1)$
BL	Fr	0	179	21	499	699	7.453*
	%	0	25.6	3.0	71.4	100	
M2	Fr	38	130	30	285	483	14.47**
	%	7.9	26.9	6.2	59	100	
M4	Fr	69	125	25	216	435	38.80**
	%	15.9	28.7	5.7	49.7	100	
M6	Fr	81	102	34	178	395	36.56**
	%	20.5	25.8	8.6	45.1	100	
M8	Fr	98	111	39	149	397	28.79**
	%	24.7	28	9.8	37.5	100	
M12	Fr	112	112	30	112	366	29.31**
	%	30.6	30.6	8.2	30.6	100	
M18	Fr	96	79	26	87	288	27.23**
	%	33.3	27.4	9	30.2	100	
M24	Fr	99	72	21	53	245	16.84**
	%	40.4	29.4	8.6	21.6	100	

Note. NS = No symptoms; Del = Only Delusions; Hal = Only Hallucinations; Del&Hall = Delusions and Hallucinations; BL = Baseline; M2 = 2 months; M4 = 4 months; M6 = 6 months; M8 = 8 months; M12 = 12 months; M18 = 18 months; M24 = 24 months. Chi-square as a test of independence was conducted, comparing delusions and hallucinations as dichotomous categories. The chi-square of goodness of fit test comparing 3 and 4 categories were significant at each time point  $\chi^2(2)_{BL} = 509.08$ ,  $\chi^2(3)_{2MO} = 349.04$ ,  $\chi^2(3)_{4MO} = 187.23$ ,  $\chi^2(3)_{6MO} = 109.35$ ,  $\chi^2(3)_{8MO} = 62.92$ ,  $\chi^2(3)_{12MO} = 55.11$ ,  $\chi^2(3)_{18MO} = 41.19$ ,  $\chi^2(3)_{24MO} = 52.71$ ,  $P_s < 0.001$ ).

**Table S7. NAPLS 3. Frequency of CHR symptoms at each time point in participants who converted to psychosis**

	NS	Del	Hall	Del&Hall	Total
BL	0	21	0	45	66
M2	2	12	0	33	45
M4	3	8	1	24	36
M6	3	2	0	16	21
M8	2	3	0	12	17
M12	3	6	0	4	13
M18	0	5	0	4	9
M24	0	1	0	1	2

Note. 66 (9.4%) participants reached a severity score of 6 during the study. On average, participants who developed psychosis did so 10.27 (SD = 9.94) months after baseline. Of those, 8.2% (5) experienced hallucinations, 54.1% (33 experienced delusions, and 37.7% (23) experienced both at conversion visit. None of the participants reported having only hallucinations at baseline.

**Table S8. NAPLS 3. Frequency of CHR symptoms at each time point in participants who persisted**

	NS	Del	Hall	Del&Hall	Total
BL	0	74	13	278	365
M2	8	71	19	195	293
M4	16	76	16	157	265
M6	21	63	24	133	241
M8	19	77	24	117	237
M12	20	87	22	98	227
M18	9	64	20	77	170
M24	0	71	21	52	144

Note. Throughout the study, symptoms persisted in 365 participants. The likelihood of having only delusions was 5.69 times greater than that of having only hallucinations ( $Z = 6.9683, P < 0.001$ ). Moreover, this likelihood was markedly higher, at 21.38 times, when compared to the occurrence of both delusions and hallucinations together ( $Z = 20.0322, P < 0.001$ ).

**Table S9. NAPLS 3. Frequency of CHR symptoms at each time point in participants who remitted**

	NS	Del	Hall	Del&Hall	Total
BL	0	57	8	114	179
M2	8	71	19	195	203
M4	50	41	8	35	134
M6	57	37	10	29	133
M8	77	31	15	20	143
M12	89	19	8	10	126
M18	87	10	6	6	109
M24	99	0	0	0	99

Note. Throughout the study, symptoms persisted in 179 participants. The likelihood of having only delusions was 7.1 times greater than that of having only hallucinations ( $Z = 6.7181, P < 0.001$ ). Moreover, this likelihood was markedly higher, at 14.25 times, when compared to the occurrence of both delusions and hallucinations together ( $Z = 11.8198, P < 0.001$ ). In the NAPLS 3 study, 14.87% (104) were assessed only at the baseline stage. These participants were not included in the symptom persistence or remitter group.

**Table S10. First symptom onset for the Del&Hall group reported retrospectively at baseline**

First Symptom	NAPLS 2		NAPLS 3	
	Frq	%	Frq	%
Delusion before Hallucinations (Del-Hall)	161	43.8%	150	40.0%
Hallucinations before Delusions (Hall-Del)	81	22.0%	104	27.3%
Same onset for Delusions and Hallucinations (D&H)	126	34.2%	121	32.2%
Total	368	100.0%	375	100.0%

Note. First symptom onset date for Del&Hall group was explored in NAPLS 2 and 3. If the difference in the onset of symptoms was larger than a month, participants were grouped Del-Hall or Hall-Del. If the data was unavailable or they reported both symptoms at baseline, they were classified in Del&Hall group.

**Table S11. PEPP. Frequency and percentage of symptoms from first prodromal symptom to 24 months**

Time		NS/O	Del	Hall	Del&Hall	Total	$\chi^2(1)$
FPr	Fr	413	131	39	NA	583	194.466**
	%	70.8	22.5	6.7	NA	100	
FPs	Fr	78	324	116	NA	518	92.987**
	%	15.1	62.5	22.4	NA	100	
FPs1	Fr	75	304	114	NA	493	84.098**
	%	15.2	61.7	16.4	NA	100	
BL	Fr	12	187	7	471	677	9.129**
	%	1.8	26.9	1	67.8	100	
M1	Fr	132	116	21	109	378	47.126**
	%	34.9	30.7	5.6	28.9	100	
M2	Fr	231	128	27	92	478	60.746**
	%	48.3	26.8	5.6	19.2	100	
M3	Fr	319	125	28	107	563	110.478**
	%	55.1	21.6	4.8	18.5	100	
M6	Fr	293	119	30	94	536	87.634**
	%	54.7	22.2	5.6	17.5	100	
M9	Fr	262	92	28	76	458	76.740**
	%	57.2	20.1	6.1	16.6	100	
M12	Fr	270	94	27	83	474	86.819**
	%	57.0	19.8	5.7	17.5	100	
M18	Fr	246	78	27	78	429	84.244**
	%	57.3	18.2	6.3	18.2	100	
M24	Fr	241	87	18	65	411	74.024**
	%	58.6	21.2	4.4	15.8	100	

Note. FPr = First prodromal symptom; FPs = First psychotic symptom; FPs1 = First psychotic symptom lasting at least one week; NS/O = No symptoms or “other” prior to baseline; Del = Delusions only; Hall = Hallucinations only; Del&Hall = Delusions and hallucinations; NA = Not applicable. FPr, FPs, and FPs1 were retrospectively collected.

**Table S12. NAPLS 2 functioning and cognitive measures at baseline**

		GAF	GFS	GFR	CDS	DSI Frq	DSI Total	MAP Task	WRAT	WASI	BACS	HLVT
	N	78	78	78	75	72	70	65	75	75	75	75
Hall - Del	M	49.14	6.26	5.78	6.56	26.44	91.51	515.84	101.04	101	54.96	24.96
	SD	9.03	1.52	2.02	5.26	23.61	73.7	164.46	16.89	15.44	13.03	5.33
	N	159	158	157	152	144	140	128	140	138	137	138
Del - Hall	M	47.7	6.23	5.91	6.72	27.64	112.26	544.8	106.25	104.58	57.45	26.25
	SD	10.42	1.6	2.27	4.63	24.91	153.79	276.61	16.16	15.45	13.55	4.67
	N	273	270	269	258	243	238	226	245	245	244	245
Del & Hall	M	49.17	6.32	6.04	5.66	26.14	99.87	502.94	103.93	103.84	57.45	26.2
	SD	11.08	1.51	2.24	4.59	20.74	88.58	210.9	15.03	14.39	12.71	5.01
	N	164	164	164	154	145	143	125	149	148	150	150
Del	M	47.49	5.8	5.95	5.55	28.23	102.97	552.97	107.82	104.83	57.1	24.98
	SD	10.78	1.59	2.11	4.65	27.02	128.4	210.51	16.97	15.36	11.25	4.98
	N	40	40	40	39	35	34	32	37	36	37	37
Hall	M	53.48	6.73	6.15	2.97	19.46	62.29	516.75	107.84	102.58	55.08	24.65
	SD	12.47	1.68	1.89	4.46	9.48	41.3	199.52	19.5	18.11	12.62	5.32

Note. GAF = Global Assessment of Functioning, measures how much a person's symptoms affect their day-to-day life on a scale of 0 to 100, those with delusion only at baseline showed lower functioning than Hall and Del-Hall ( $F_{4,705} = 3.001, P = 0.018, \eta^2 = .017, \text{Del} < \text{Hall} > \text{Hall-Del}$ ); GFS = Global Functioning Social Scale rated from 1 to 10, with high scores indicating better functioning, Del only at baseline showed lower scores

than Hall and Del&Hall ( $F_{4,705} = 4.202, P = 0.002, \eta^2 = .023$ , Del < Hall & Del-Hall,  $P_s < 0.05$ ); GFR = Global Functioning Role scale, rated from 1 to 10, with high scores indicating better functioning ( $\eta^2 = .002, P_s = ns$ ); CDS = Calgary Depression Scale ( $F_{4,673} = 5.686, P < 0.001, \eta^2 = .033$ , H < all groups,  $P_s < 0.05$ ); DSI Frq = Daily Stress Inventory frequency of events ( $\eta^2 = .007, P = ns$ ); DSI total = Daily Stress Inventory average of distress ( $\eta^2 = .009, P = ns$ ); MAP Task = Functional Capacity Map Task (Blocks) ( $\eta^2 = .005, P = ns$ ); WRAT reading = Wide Range Achievement Test reading standard scores ( $F_{4,641} = 2.967, P = 0.019$ , no significant pairwise comparisons); WASI = Wechsler Abbreviated Scale of Intelligence ( $P = ns$ ); BACS = Brief Assessment of Cognition in Schizophrenia, Symbol Coding ( $\eta^2 = .005, P = ns$ ); HLVT = Hopkins Verbal Learning Test–Revised ( $F_{4,640} = 2.644, P = 0.033, \eta^2 = .016$ , no significant pairwise comparisons  $P_s = ns$ ). Participants who transitioned to psychosis performed similarly on functioning (GAF, GFS, GFR, MAP Task), level of depression (CDS), frequency of distress events (DSI Frq), and distress (DSI) compared with those who didn't convert. However, converters did poorly on BACS ( $T_{(641)} = 2.795, P = 0.003$ ) and HLVT ( $T_{(643)} = 2.524, P = 0.006$ ).

**Table S13. NAPLS 3 functioning and cognitive measures at baseline**

		GAF	GFS	GFR	CDS	DSI Frq	DSI Total	Go to Town	WRAT	WASI	BACS	HLVT
	N	104	104	57	103	100	97	99	100	101	101	101
Hall - Del	M	52.66	6.81	1.47	6.11	21.72	76.53	3.82	107.01	102.54	52.48	26.11
	SD	12.737	1.401	0.889	4.43	12.129	54.334	2.915	17.133	16.646	13.812	5.51
	N	152	154	86	152	149	148	137	147	147	148	148
Del - Hall	M	49.48	6.35	1.49	6.99	21.23	75.26	3.53	111.57	106.05	56.07	26.82
	SD	12.004	1.462	0.837	4.565	11.597	57.259	2.865	18.884	15.819	13.246	5.477
	N	238	239	135	233	223	223	216	230	228	228	227
Del & Hall	M	50.39	6.43	1.39	6.67	21.85	75.1	3.56	108.67	106.52	55.84	26.44
	SD	11.876	1.487	0.81	4.495	11.335	56.748	2.907	17.233	14.971	13.063	5.035
	N	179	179	96	178	172	171	168	176	176	177	177
Del	M	50.75	6.14	1.61	5.81	18.83	59.23	3.67	110.37	105.62	52.42	26.09
	SD	10.974	1.596	0.91	4.191	10.117	43.43	3.259	16.319	17.183	13.576	5.056
	N	21	21	1	21	20	19	21	21	21	21	21
Hall	M	60.81	7.48	1	3.57	13.4	29.68	4.43	109.43	104.38	54.57	26.67
	SD	13.129	1.537	-	3.429	7.701	22.413	2.675	15.5	13.204	9.347	4.127

Note. GAF = Global Assessment of Functioning, ( $F_{4,689} = 4.906, p < .001, \eta^2 = .028$ , Hall > all groups,  $P_s < .05$ ); GFS = Global Functioning Social scale, ( $F_{4,692} = 5.987, P < .001, \eta^2 = .033$ , Hall > Del-Hall, Del&Hall and Del; Del < Hall-Del and Hall,  $P_s < .05$ ); GFR = Global

Functioning Role scale; GFR = Global Functioning Role scale ( $\eta^2 = .012$ ); CDS = Calgary Depression Scale, ( $F_{4,692} = 3.957, P = .003, \eta^2 = .023$ ; Hall < Del-Hall and Del&Hall,  $P_s < .05$ ); DSI Frq = Daily Stress Inventory frequency of events ( $F_{4,659} = 4.257, P < .001, \eta^2 = .025$ ; Hall < all groups except Del,  $P_s < .05$ ); DSI total = Daily Stress Inventory average of distress ( $F_{4,659} = 4.257, P = .002, \eta^2 = .035$ ; Hall < all groups except Del,  $P_s < .05$ ); Go to Town = Functional Capacity (errands completed) ( $P = ns, \eta^2 = .003$ ); WRAT reading = Wide Range Achievement Test reading standard scores ( $F_{4,636} = 4.684, P = .001, \eta^2 = .008$ ; no significant differences after multiple comparisons); WASI = Wechsler Abbreviated Scale of Intelligence ( $P = ns, \eta^2 = .007$ ); BACS = Brief Assessment of Cognition in Schizophrenia, Symbol Coding,  $F_{(4,670)} = 2.779, P = .026, \eta^2 = .016$ , do not suvided multiple comparisons; HLVT = Hopkins Verbal Learning Test–Revised ( $P = ns, \eta^2 = .003$ ). Participants who transitioned to psychosis performed poorly in cognitive and daily functioning compared with those who didn't convert ( $T_{GAF(692)} = 3.995, P < 0.000$ ;  $T_{GFS(695)} = 3.091, P = 0.002$ ;  $T_{BACS(673)} = 2.772, P = 0.006$ ;  $T_{HLVT(672)} = 2.099, P = 0.036$ ;  $T_{WASI(671)} = 2.213, P = 0.027$ ), but they have the same levels of depression (CDS), frequency of daily stress events (DSI Frq) and daily stress events (DSI), same performance on WRAT and the Go to Town Task.

**Table S14. Prevalence in percentages of DSM-IV diagnoses at baseline in NAPLS 2 and NAPLS 3 samples**

	NAPLS 2					NAPLS 3				
	Hall - Del (n = 79)	Del - Hall (n = 156)	Del&Hall (n = 265)	Hall (n = 39)	Del (n = 160)	Hall - Del (n = 104)	Del - Hall (n = 153)	Del&Hall (n = 236)	Hall (n = 21)	Del (n = 179)
Depression	50.63	53.21	36.98	28.21	44.37	50	53.59	49.58	23.81	44.13
Bipolar	3.8	9.62	6.04	0	9.37	6.73	9.87	5.51	0	6.15
OCD	7.59	7.05	6.79	2.56	7.5	12.5	9.15	12.71	0	9.5
PTSD	2.53	2.56	3.4	2.56	0	10.58	5.88	8.9	0	7.26
Panic Disorder	12.66	14.1	11.32	0	10	24.04	17.65	23.73	14.29	11.17
Agoraphobia	1.27	0.64	1.89	0	0	8.65	7.84	9.75	0	3.35
Social Phobia	11.39	19.23	13.21	10.26	14.37	22.12	23.53	22.88	4.76	22.91
Specific Phobias	10.13	13.46	10.19	17.95	5.62	10.58	7.19	10.17	9.52	5.59
GAD	26.58	23.08	20.75	17.95	28.12	30.77	28.76	29.24	23.81	34.64
ADHD	18.99	18.59	15.09	28.95	18.75	22.12	18.3	16.95	23.81	17.32
BPD	9.33	3.4	4.37	0	1.91	1.92	1.96	6.36	4.76	5.59
SPD	16.46	14.74	21.51	5.13	19.88	8.65	10.46	13.98	0	11.73

Note. DSM-IV diagnoses based on the Structured Clinical Interview for DSM-IV (SCID-IV); Bipolar = Bipolar Disorder; OCD = Obsessive-Compulsive Disorder; PTSD = Post-Traumatic Stress Disorder; GAD = Generalized Anxiety Disorder; ADHD = Attention-Deficit/ Hyperactivity Disorder; BPD = Borderline Personality Disorder; SPD = Schizotypal Personality Disorder.

**Table S15. Prevalence of diagnoses at baseline in the PEPP sample of first reported prodromal, first reported psychotic symptoms and based on symptoms present at baseline**

	First Prodromal Symptom		First Psychotic Symptom		Baseline (study start)		
	Hall only (n = 39)	Del only (n = 131)	Hall only (n = 116)	Del only (n = 324)	Hall & del (n = 471)	Hall only (n = 7)	Del only (n = 187)
SOFAS	M: 41.08 (13.383)	M: 43.34 (12.790)	M: 42.50 (11.797)	M: 40.14 (12.066)	M: 40.49 (13.053)	M: 53.86 (16.945)	M: 41.09 (12.692)
Schizophrenia	17 (43.59%)	61 (46.56%)	46 (39.66%)	119 (36.73%)	176 (37.37%)	2 (28.57%)	61 (32.62%)
Psychosis NOS	10 (25.64%)	16 (12.21%)	20 (17.24%)	54 (16.67%)	72 (15.29%)	2 (28.57%)	25 (13.37%)
Schizoaffective disorder	3 (7.69%)	7 (5.34%)	9 (7.76%)	19 (5.86%)	39 (8.28%)	0 (0%)	8 (4.28%)
Schizophreniform disorder	3 (7.69%)	8 (6.11%)	4 (3.45%)	10 (3.09%)	20 (4.25%)	0 (0%)	3 (1.60%)
Brief psychotic disorder	0 (0%)	0 (0%)	0 (0%)	1 (0.31%)	1 (0.21%)	1 (14.29%)	0 (0%)
Delusional disorder	0 (0%)	8 (6.11%)	0 (0%)	7 (2.16%)	2 (0.42%)	0 (0%)	9 (4.81%)
Substance-induced psychosis	1 (2.56%)	2 (1.53%)	0 (0%)	2 (0.62%)	1 (0.21%)	1 (14.29%)	2 (1.07%)
Bipolar Disorder	2 (5.13%)	20 (15.27%)	14 (12.07%)	60 (18.52%)	66 (14.01%)	1 (14.29%)	36 (19.25%)
Depression*	10 (25.64%)	21 (16.03%)	19 (16.38%)	54 (16.67%)	75 (15.92%)	2 (28.57%)	19 (10.16%)
Major depression with psychotic features	3 (7.69%)	10 (7.63%)	21 (18.10%)	49 (15.12%)	55 (11.68%)	0 (0%)	22 (11.76%)
Mood Disorder	0 (0%)	1 (0.76%)	0 (0%)	1 (0.31%)	1 (0.21%)	0 (0%)	0 (0%)

NOS

Substance-induced mood disorder	0 (0%)	0 (0%)	1 (0.86%)	0 (0%)	1 (0.21%)	0 (0%)	0 (0%)
Anxiety disorder	0 (0%)	14 (10.69%)	10 (8.62%)	28 (8.64%)	35 (7.43%)	0 (0%)	12 (6.42%)
Panic disorder	1 (2.56%)	4 (3.05%)	3 (2.59%)	11 (3.40%)	14 (2.97%)	0 (0%)	2 (1.07%)
OCD	1 (2.56%)	2 (1.53%)	5 (4.31%)	2 (0.62%)	7 (1.49%)	0 (0%)	2 (1.07%)
PTSD	1 (2.56%)	1 (0.76%)	5 (4.31%)	4 (1.23%)	7 (1.49%)	0 (0%)	3 (1.60%)
Alcohol abuse	8 (20.51%)	22 (16.79%)	22 (18.97%)	50 (15.43%)	69 (14.65%)	2 (28.57%)	25 (13.37%)
Substance abuse	21 (53.85%)	84 (64.12%)	61 (52.59%)	196 (60.49%)	249 (52.87%)	3 (42.86%)	99 (52.94%)
Hallucinogen dependence	0 (0%)	0 (0%)	0 (0%)	1 (0.31%)	1 (0.21%)	0 (0%)	1 (0.53%)
Eating disorder	0 (0%)	0 (0%)	1 (0.86%)	0 (0%)	1 (0.21%)	0 (0%)	0 (0%)
ADHD	0 (0%)	1 (0.76%)	1 (0.86%)	1 (0.31%)	2 (0.42%)	0 (0%)	0 (0%)
Agoraphobia	0 (0%)	0 (0%)	0 (0%)	3 (0.93%)	2 (0.42%)	0 (0%)	2 (1.07%)
Hypochondriasis	1 (2.56%)	0 (0%)	1 (0.86%)	0 (0%)	1 (0.21%)	0 (0%)	0 (0%)
Social phobia	2 (5.13%)	6 (4.58%)	8 (6.90%)	13 (4.01%)	17 (3.61%)	0 (0%)	5 (2.14%)
Specific phobia	0 (0%)	0 (0%)	0 (0%)	1 (0.31%)	2 (0.42%)	0 (0%)	0 (0%)

\* Includes Dysthymia

**Table S16. NAPLS 2, odds ratios for conversion by symptoms at baseline and symptom onset.**

Symptom	Baseline			Symptom	First Symptom		
	Hall	Del	Del&Hal 1		Hall	Del	Del&Hall
Hall (n = 4)	1			Hall (n = 9)	1		
Del (n = 14)	1.20	1		Del (n = 35)	1.49	1	
Del&Hall (n = 55)	1.08	0.77	1	Del&Hall (n = 29)	1.45	0.98	1

**Note.** The table on the left shows the odds ratios of the symptoms at baseline, while the table on the right shows the odds ratios of first reported symptoms retrospectively. At baseline, individuals with only delusions had a slightly higher chance of converting than those with only hallucinations. The same trend was observed between delusions and hallucinations at baseline versus only hallucinations. Participants with only delusions had slightly fewer chances of conversion than those with both symptoms. No statistical differences were found in the proportions of conversion between the different baseline symptom presentations (Del vs Hall:  $Z = 0.3038$ , Hall vs Del&Hall;  $Z = 0.1383$ , Del vs Del&Hall:  $Z = 0.8195$ ,  $P_s = ns$ ). The same trend was observed when the conversion rates for the first reported retrospective symptom were analyzed (Del first vs Hall first  $Z = 1.0343$ , Hall first vs Del&Hall;  $Z = 1.0343$ ; Del first vs Del&Hall  $Z = 0.1015$ ,  $P_s = ns$ ).

**Table S17. NAPLS 3, odds ratios for conversion by symptom onset.**

Symptom	Baseline			Symptom	First Symptom		
	Hall	Del	Del&Hal 1		Hall	Del	Del&Hall
Hall (n = 0)	1			Hall (n = 9)	1		
Del (n = 21)	-	1		Del (n = 35)	2.20	1	
Del&Hall (n = 45)	-	1.34	1	Del&Hall (n = 29)	2.54	0.87	1

The table on the left displays the odds ratios of symptoms at the baseline, while the table on the right shows the odds ratios of first reported symptoms retrospectively. The same trend as NAPLS 2 was observed in the NAPLS 3 sample. However, participants who presented only hallucinations at baseline did not experience any conversions. The odds ratios considering the first symptom reported retrospectively indicated that the conversion rates were double for those who had delusions first as compared to those who had only hallucinations first. The same trend was observed for participants who reported retrospectively starting with both symptoms as compared to those who had only hallucinations. Finally, the ratio of conversion between delusions and both symptoms reported retrospectively was slightly lower for delusion only. No statistical differences were found in the conversion proportions between the different baseline symptom presentations (Del vs Del&Hall:  $Z = 1.0508$ ,  $P = ns$ ). The same trend was observed when the conversion rates for the first reported retrospective symptom were analyzed (Del vs Del&Hall:  $Z = 1.0508$ ,  $P = ns$ , and as a first symptom: Del first vs Hall first  $Z = 1.3162$ , Hall first vs Del&Hall;  $Z = 1.6086$ ; Del first vs Del&Hall  $Z = 0.5169$ ,  $P_s = ns$ ).

**Table S18. NAPLS 2, symptom transition probabilities from visit to visit**

Visit	Symt	NS		D		H		DH		Total
		Fr	%	Fr	%	Fr	%	Fr	%	
BL to M6	NS	0	0	0	0	0	0	0	0	0
	D	29	26.4%	68	<b>61.8%</b>	2	1.8%	11	10.0%	110
	H	16	48.5%	2	6.1%	8	<b>24.2%</b>	7	21.2%	33
	DH	59	17.2%	67	19.5%	26	7.6%	191	<b>55.7%</b>	343
	Total	105		136		36		209		486
M6 to M12	NS	58	<b>72.5%</b>	13	16.3%	7	8.8%	2	2.5%	80
	D	23	24.7%	50	<b>53.8%</b>	3	3.2%	17	18.3%	93
	H	10	35.7%	2	7.1%	13	<b>46.4%</b>	3	10.7%	28
	DH	14	9.2%	33	21.7%	12	7.9%	93	<b>61.2%</b>	152
	Total	105		98		35		115		353
M12 to M18	NS	53	<b>82.8%</b>	8	12.5%	1	1.6%	2	3.1%	64
	D	20	29.4%	36	<b>52.9%</b>	1	1.5%	11	16.2%	68
	H	11	44.0%	3	12.0%	8	<b>32.0%</b>	3	12.0%	25
	DH	10	11.5%	27	31.0%	9	10.3%	41	<b>47.1%</b>	87
	Total	94		74		19		57		244
M18 to M24	NS	65	<b>81.3%</b>	7	8.8%	6	7.5%	2	2.5%	80
	D	11	18.0%	36	<b>59.0%</b>	2	3.3%	12	19.7%	61
	H	5	27.8%	1	5.6%	10	<b>55.6%</b>	2	11.1%	18
	DH	4	8.5%	7	14.9%	3	6.4%	33	<b>70.2%</b>	47
	Total	85		51		21		49		206

Note. NS = No symptoms; D = Only delusions; H = Only hallucinations; DH = Delusions and hallucinations; Symt = Symptom; Fr = Frequency; BL = Baseline; M6 = 6 months; M12 = 12 months; M18 = 18 months; M24 = 24 months. Bold values indicate the probabilities of remaining with the same symptom from one time point to the next one (e.g., 61.8% of cases who reported only delusions at baseline persist with the same symptom at the 6-month follow-up).

**Table S19. NAPLS 3 symptom transitions probabilities from visit to visit**

Visit	Symt	NS		D		H		DH		Total
		Fr	%	Fr	%	Fr	%	Fr	%	
BL to M2	NS	0	0	0	0	0	0	0	0	0
	D	18	14.6%	84	<b>68.3%</b>	1	0.8%	20	16.3%	123
	H	3	15.8%	0	0.0%	14	<b>73.7%</b>	2	10.5%	19
	DH	17	5.0%	46	13.5%	15	4.4%	263	<b>77.1%</b>	341
	Total	38		130		30		285		483
M2 to M4	NS	26	<b>96.3%</b>	1	3.7%	0	0.0%	0	0.0%	27
	D	15	17.0%	65	<b>73.9%</b>	0	0.0%	8	9.1%	88
	H	7	28.0%	0	0.0%	14	<b>56.0%</b>	4	16.0%	25
	DH	14	6.5%	36	16.8%	9	4.2%	155	<b>72.4%</b>	214
	Total	62		102		23		167		354
M4 to M6	NS	45	<b>86.5%</b>	3	5.8%	1	1.9%	3	5.8%	52
	D	16	18.0%	56	<b>62.9%</b>	0	0.0%	17	19.1%	89
	H	2	9.5%	1	4.8%	15	<b>71.4%</b>	3	14.3%	21
	DH	5	3.3%	17	11.2%	11	7.2%	119	<b>78.3%</b>	152
	Total	68		77		27		142		314
M6 to M8	NS	50	<b>70.4%</b>	9	12.7%	9	12.7%	3	4.2%	71
	D	18	23.1%	53	<b>67.9%</b>	0	0.0%	7	9.0%	78
	H	6	21.4%	2	7.1%	16	<b>57.1%</b>	4	14.3%	28
	DH	5	3.5%	22	15.5%	11	7.7%	104	<b>73.2%</b>	142
	Total	79		86		36		118		319
M8 to M12	NS	68	<b>86.1%</b>	6	7.6%	3	3.8%	2	2.5%	79
	D	14	16.1%	60	<b>69.0%</b>	0	0.0%	13	14.9%	87
	H	8	24.2%	2	6.1%	16	<b>48.5%</b>	7	21.2%	33
	DH	9	7.8%	27	23.3%	7	6.0%	73	<b>62.9%</b>	116
	Total	99		95		26		95		315
M12 to M18	NS	56	<b>74.7%</b>	14	18.7%	4	5.3%	1	1.3%	75
	D	18	23.1%	46	<b>59.0%</b>	2	2.6%	12	15.4%	78
	H	2	8.7%	2	8.7%	10	<b>43.5%</b>	9	39.1%	23
	DH	6	7.5%	13	16.3%	8	10.0%	53	<b>66.3%</b>	80
	Total	82		75		24		75		256
M18 to M24	NS	60	<b>87.0%</b>	7	10.1%	1	1.4%	1	1.4%	69
	D	10	18.2%	38	<b>69.1%</b>	1	1.8%	6	10.9%	55
	H	6	33.3%	1	5.6%	8	<b>44.4%</b>	3	16.7%	18
	DH	6	9.8%	12	19.7%	8	13.1%	35	<b>57.4%</b>	61
	Total	82		58		18		45		203

Note. NS = No symptoms; Del = Only Delusions; Hall = Only Hallucinations; Del&Hall = Delusions and Hallucinations; Symt = Symptom; Fr = Frequency; BL = Baseline; M2 = 2 months; M4 = 4 months; M6 = 6 months; M8 = 8 months; M12 = 12 months; M18 = 18 months; M24 = 24 months. Bold values indicate the probabilities of remaining with the same symptom from one time point to the next one (e.g., 68.3% of cases who reported only delusions at baseline persist with the same symptom at the 6-month follow-up).

**Table S20. PEPP symptom probability transitions from visit to visit**

Visit	Symt	NS/O		Del		Hall		Del&Hall		Total
		Fr	%	Fr	%	Fr	%	Fr	%	
FPr to FPs	O	65	18.6%	209	59.9%	75	21.4%	0	NA	349
	D	6	5.9%	86	<b>85.1%</b>	9	8.9%	0	NA	101
	H	2	6%	7	21.2%	24	<b>72.7%</b>	0	NA	33
	DH	0	NA	0	NA	0	NA	0	NA	0
	Total	73		302		108		0		483
FPs to FPs1	O	72	<b>96%</b>	2	2.7%	1	1.3%	0	NA	75
	D	3	0.9%	301	<b>97.7%</b>	4	1.3%	0	NA	308
	H	0	0%	1	0.9%	109	<b>99.1%</b>	0	NA	110
	DH	0	NA	0	NA	0	NA	0	NA	0
	Total	75						0		493
FPs1 to BL	O	5	<b>6.8%</b>	25	<b>34.2%</b>	2	2.7%	41	56.2%	73
	D	0	0%	101	33.9%	0	0%	197	66.1%	298
	H	1	0.8%	5	4.5%	0	0%	106	<b>94.6%</b>	112
	DH	0	NA	0	NA	0	NA	0	NA	0
	Total	6		131		2		344		483
BL to M1	NS	3	50%	2	33.3%	1	16.7%	0	0%	6
	D	39	37.5%	61	<b>58.7%</b>	0	0%	4	3.8%	104
	H	2	<b>66.7%</b>	0	0%	1	<b>33.3%</b>	0	<b>42.8%</b>	3
	DH	66	26.4%	58	23.2%	19	7.6%	107	30.6%	250
	Total	110		121		21		111		363
M1 to M2	NS	100	<b>87.0%</b>	12	10.4%	2	1.7%	1	0.9%	115
	D	40	39.2%	56	<b>54.9%</b>	3	2.9%	3	2.9%	102
	H	11	61.1%	1	5.6%	2	<b>11.1%</b>	4	22.2%	18
	DH	19	19.4%	20	20.4%	9	9.2%	50	<b>51.0%</b>	98
	Total	170		89		16		58		333
M2 to M3	NS	192	<b>86.5%</b>	17	7.7%	5	2.3%	8	3.6%	222
	D	41	33.9%	68	<b>56.2%</b>	1	0.8%	11	9.1%	121
	H	14	53.8%	0	0.0%	6	<b>23.1%</b>	6	23.1%	26
	DH	20	23.3%	11	12.8%	8	9.3%	47	<b>54.7%</b>	86
	Total	267		96		20		72		455
M3 to M6	NS	218	<b>79.3%</b>	31	11.3%	7	2.5%	19	6.9%	275
	D	36	33.0%	60	<b>55.0%</b>	1	0.9%	12	11.0%	109
	H	8	29.6%	2	7.4%	8	<b>29.6%</b>	9	33.3%	27
	DH	19	19.6%	19	19.6%	14	14.4%	45	<b>46.4%</b>	97
	Total	281		112		30		85		508
M6 to M9	NS	190	<b>80.5%</b>	30	12.7%	6	2.5%	10	4.2%	236
	D	35	37.6%	45	<b>48.4%</b>	4	4.3%	9	9.7%	93
	H	9	42.9%	0	0.0%	4	<b>19.0%</b>	8	38.1%	21
	DH	11	16.7%	6	9.1%	11	16.7%	38	<b>57.6%</b>	66
	Total	245		81		25		65		416
M9 to M12	NS	175	<b>76.4%</b>	30	13.1%	6	2.6%	18	7.9%	229

	D	34	41.0%	38	<b>45.8%</b>	1	1.2%	10	12.0%	83
	H	11	45.8%	2	8.3%	5	<b>20.8%</b>	6	25.0%	24
	DH	16	23.2%	11	15.9%	7	10.1%	35	<b>50.7%</b>	69
	Total	236		81		19		69		405
M12 to M18	NS	170	<b>78.3%</b>	23	10.6%	6	2.8%	18	8.3%	217
	D	30	38.0%	36	<b>45.6%</b>	3	3.8%	10	12.7%	79
	H	6	26.1%	3	13.0%	8	<b>34.8%</b>	6	26.1%	23
	DH	14	22.2%	10	15.9%	6	9.5%	33	<b>52.4%</b>	63
	Total	220		72		23		67		382
M18 to M24	NS	166	<b>78.3%</b>	30	14.2%	3	1.4%	13	6.1%	212
	D	22	34.4%	32	<b>50.0%</b>	0	0.0%	10	15.6%	64
	H	6	26.1%	3	13.0%	6	<b>26.1%</b>	8	34.8%	23
	DH	19	28.8%	16	24.2%	6	9.1%	25	<b>37.9%</b>	66
	Total	213		81		15		56		365

Note. Symt = Symptom; FPr = First prodromal symptom; FPs = First Psychotic Symptom; FPs1 = First Psychotic Symptom lasting at least one week; NS/O = No symptoms/Other prior to baseline; D = Only Delusions; H = Only Hallucinations; DH = Delusions and Hallucinations. Proportions were computed based on the number of participants with the symptoms from the previous visits as conditional probabilities.

**Table 21. Comparisons of transition probabilities**

Comparisons	NAPLS 2		NAPLS 3		PEPP	
	Z-Value	P-Value	Z-Value	P-Value	Z-Value	P-Value
<b>No symptoms (NS)</b>						
NS to NS vs NS to D	14.04	< 0.001	19.05	< 0.001	37.91	< 0.001
NS to NS vs NS to H	15.49	< 0.001	20.81	< 0.001	43.5	< 0.001
NS to NS vs NS to HD	16.35	< 0.001	19.84	< 0.001	41.39	< 0.001
NS to D vs NS to H	2.269	0.023	3.008	0.0027	9.92	< 0.001
NS to D vs NS to HD	3.92	< 0.001	1.25	0.21	5.69	< 0.001
NS to H vs NS to HD	1.83	0.067	-1.79	0.074	-4.69	< 0.001
<b>Delusions (D)</b>						
D to NS vs D to D	-9.67	< 0.001	-17.33	< 0.001	-6.16	< 0.001
D to NS vs D to H	7.49	< 0.001	10.40	< 0.001	17.25	< 0.001
D to NS vs D to HD	1.92	0.055	3.62	< 0.001	12.74	< 0.001
D to D vs D to H	15.57	< 0.001	24.50	< 0.001	22.18	< 0.001
D to D vs D to HD	11.35	< 0.001	20.18	< 0.001	18.23	< 0.001
D to H vs D to HD	-5.88	< 0.001	-7.57	< 0.001	-6.36	< 0.001
<b>Hallucinations (H)</b>						
H to NS vs H to D	5.52	< 0.001	4.11	< 0.001	7.26	< 0.001
H to NS vs H to H	0.43	0.67	-5.67	< 0.001	3.18	0.0015
H to NS vs H to HD	4.2	< 0.001	-18.22	< 0.001	2.32	0.021
H to D vs H to H	-5.14	< 0.001	-9.01	< 0.001	-4.42	< 0.001
H to D vs H to HD	-1.55	0.122	-20.4	< 0.001	-5.21	< 0.001
H to H vs H to HD	3.8	< 0.001	-13.74	< 0.001	-0.87	0.382
<b>Hallucinations and Delusions (HD)</b>						
HD to NS vs HD to D	-3.48	< 0.001	-7.65	< 0.001	2.03	0.042
HD to NS vs HD to H	3.35	< 0.001	-0.63	0.529	7.01	< 0.001
HD to NS vs HD to HD	-16	< 0.001	-32.85	< 0.001	-10.27	< 0.001
HD to D vs HD to H	6.702	< 0.001	7.084	< 0.001	5.029	< 0.001
HD to D vs HD to HD	-12.94	< 0.001	-27.6	< 0.001	-12.18	< 0.001
HD to H vs HD to HD	-18.55	< 0.001	-32.5	< 0.001	-16.59	< 0.001

Note. Comparisons between proportions from initial state to following state were performed using proportion differences. P values are not adjusted for multiple comparisons. PEPP comparisons were performed from baseline to 24 months.

**Table S22. Time in months lapsed between the onset of the first and second symptoms in CHR-P and FEP samples**

	NAPLS 2				NAPLS 3				PEPP
	From Baseline		Retrospective		From Baseline		Retrospective		Prodrome Length
	Hall-Del	Del-Hall	Hall-Del	Del-Hall	Hall-Del	Del-Hall	Hall-Del	Del-Hall	First symptom to baseline
N	12	28	80	159	7	47	104	150	591
Mean	10.33	11.35	22.22	22.05	8.71	6.02	23.50	28.34	22.92
SD	8.2	5.66	25.31	27.95	6.10	5.61	27.82	35.48	38.09
Median	6	11	11	12	8	4	12	12	6.97
Min	5	5	1	1	2	1	1	1	0
Max	28	25	104	172	18	24	128	208	231.2
IQR	7.5	8	26	23	6	6	18.5	37	27.46

Note. Hall-Dell = participants who reported retrospectively having hallucinations as first symptom and then developed delusions; Dell-Hall = participants who reported retrospectively having delusions as first symptom and then developed hallucinations; IQR = Interquartile range. For participants who reported delusions or hallucinations at baseline and later experienced the other symptom, the time of onset for the second symptom was recorded from the baseline until the first occurrence of the second symptom during the study (From Baseline). For those who reported both delusions and hallucinations at baseline, we tracked the onset of symptoms retrospectively to report the time lapse between the symptoms (Retrospective). The prodrome length was measured in PEPP sample, considering the onset of the first prodrome symptom (hallucination or delusion) to the first psychotic symptom at baseline. No significant differences in time lapsed between hallucinations and delusions were found.

**Table S23. Lempel Ziv Complexity index for hallucination and delusions**

	NAPLS 2		NAPLS 3		PEPP	
	Del	Hall	Del	Hall	Del	Hall
N	383	337	301	260	598	473
Mean	1.22	1.29	1.06	1.11	1.24	1.25
SEM	0.01	0.01	0.02	0.02	0.01	0.01
Median	1.05	1.39	1.13	1.13	1.20	1.20
Mode	1.39	1.39	0.75	1.20	1.05	1.05
SD	0.27	0.56	0.27	0.29	0.27	0.26
Minimum	0.92	0.92	0.75	0.70	0.70	0.70
Maximum	1.85	1.87	2.00	1.85	2.00	2.01

Note. LZC values are standardized values.

For the purposes of this study, the presence or absence of hallucinations and delusions in the prospective sample was established using the SAPS questions 7 (global assessment of hallucinations) and 20 (global assessment of delusions); scores of 0 (none) and 1 (questionable) were coded as ‘absent’ and scores of 2 (mild) and above were coded as present. While symptomatic remission of symptoms on the SAPS is often considered to be present at mild symptoms and below,<sup>15</sup> our choice for binarization was made as we were interested in following subtle changes in symptoms over time that might reflect underlying computational processes. In addition, as this was a treated sample, examining mild symptoms allowed for the assessment of symptoms that were present though symptomatically controlled by medication, which is likely relevant to understanding symptom transitions over time. In Table S24, we provide the data on symptom prevalence at each timepoint using the clinical cutoff of 3 points. As can be seen, the patterns observed- with delusions, and delusions and hallucinations being more common than hallucinations- are maintained from the analysis with the alternative cutoff.

**Table S24. PEPP. Frequency and percentage of symptoms from baseline PEPP admission to 24 months using the 3 or greater as a cutoff on the SAPS items**

Time		NS/O	Del	Hall	Del&Hall	Total
BL	F	29	242	21	385	677
	r					
	%	4.3	35.7	3.1	56.9	100
M1	F	184	97	32	65	378
	r					
	%	48.7	25.7	8.5	17.2	100
M2	F	318	77	28	55	478
	r					
	%	66.5	16.1	5.9	11.5	100
M3	F	410	76	37	56	563
	r					
	%	70.8	13.1	6.4	9.7	100
M6	F	386	70	32	48	536
	r					
	%	72	13.1	6	9	100
M9	F	339	50	32	37	458
	r					
	%	74	10.9	7	8.1	100
M12	F	360	42	24	48	474
	r					
	%	75.9	8.9	5.1	10.1	100
M18	F	319	39	33	38	429
	r	74.4	9.1	7.7	8.9	100
	%					
M24	F	314	45	13	39	411
	r					
	%	76.4	10.9	3.2	9.5	100

Note. NS= No symptoms (score of absent, questionable, or mild on SAPS item); Del = Delusions only; Hall = Hallucinations only; Del&Hall = Delusions and hallucinations

**Table S25. NAPLS 2, Total symptom severity, Perceptual Abnormalities (P4), Unusual Thought Content (P1), and Suspiciousness or Persecutory Ideas (P2)**

		Total Scale of Psychosis-risk Symptoms (SOPS)					Perceptual Abnormalities and Hallucinations (P4)					Unusual Thought Content (P1) & Suspiciousness or Persecutory Ideas (P2)				
		BL	6M	12M	18M	24M	BL	6M	12M	18M	24M	BL	6M	12M	18M	24M
Hall-Del	N	76	58	40	32	32	80	58	40	32	32	80	58	40	32	32
	M	39.5	30.1	27	24.7	22	3.9	2.8	2.1	1.6	1.8	3.7	3.1	2.8	2.3	2.3
	SD	11.3	13.2	11.4	11.5	12.2	0.7	1.5	1.4	1.4	1.4	0.7	1.4	1.5	1.5	1.5
Del-Hall	N	156	107	90	59	59	158	108	90	59	59	158	108	90	59	59
	M	42.2	32.5	28.6	28.1	26.1	3.6	2.6	2.2	2	1.8	4.1	3.4	3	2.8	2.8
	SD	11.4	13.7	13.5	14.1	12.2	0.7	1.6	1.6	1.6	1.5	0.7	1.1	1.3	1.4	1.3
Del&Hall	N	262	177	153	103	102	275	178	153	104	102	275	178	153	104	102
	M	38.2	28.8	25.8	23.5	25.4	3.9	2.6	2.4	2	1.9	3.9	3	2.8	2.5	2.3
	SD	11	13.3	12.3	13.9	15.4	0.7	1.5	1.6	1.6	1.7	0.8	1.4	1.4	1.6	1.6
Del	N	160	110	85	49	53	165	110	85	49	53	165	110	85	49	53
	M	37.1	28	25	24	23.2	1	0.9	1	1.1	0.8	3.9	2.9	2.5	2.5	2.5
	SD	11.7	12.9	13.4	13.8	13.4	0.9	1.3	1.4	1.3	1.2	0.8	1.3	1.3	1.2	1.3
Hall	N	39	33	25	18	17	40	33	25	18	17	40	33	25	18	17

M	26.1	19.5	19	16.9	16	3.8	2	1.6	1.6	1.4	1.2	1.7	1.3	1.1	1.1
SD	12.4	11.7	11.4	11.7	9.6	0.7	1.6	1.5	1.8	1.4	0.8	1.4	1.2	1.4	1.2

Note. Hall-Dell = participants who reported retrospectively having hallucinations as first symptom and then developed delusions; Dell-Hall = participants who reported retrospectively having delusions as first symptom and then developed hallucinations; Del&Hall = participants who reported delusions and hallucinations at the same onset; Del = participants that reported delusions as a first symptom; Hall = participants who reported hallucinations as a first symptom.

**Table S26. NAPLS 2, Disorganized, Negative, General, and Positive Symptoms.**

	SOPS Disorganized Symptoms			SOPS Negative Symptoms			SOPS Positive Symptoms			SOPS General Symptoms		
	N	M	SD	N	M	SD	N	M	SD	N	M	SD
Hall-Del	76	5.00	2.766	76	12.20	5.683	80	12.35	2.605	76	10.04	4.165
Del-Hall	156	5.53	3.076	156	13.06	5.964	159	13.69	2.955	156	9.96	4.258
Del&Hall	263	5.10	3.158	262	11.14	5.825	275	12.86	3.197	262	9.13	4.010
Hall	39	4.38	3.361	39	8.64	6.372	40	7.18	2.678	39	6.00	4.668
Del	161	5.17	3.067	161	12.66	6.101	165	10.46	3.247	160	8.84	4.262
Total	695	5.16	3.092	694	11.90	6.026	719	12.12	3.482	693	9.17	4.265

Note. Hal-Dell = participants who reported retrospectively having hallucinations as first symptom and then developed delusions; Dell-Hall = participants who reported retrospectively having delusions as first symptom and then developed hallucinations; Del&Hall = participants who reported delusions and hallucinations at the same onset; Del = participants that reported delusions as a first symptom; Hall = participants who reported hallucinations as first symptoms. No significant differences were found for Disorganized symptoms. Negative symptoms ( $F_{4,689} = 6.232, P < 0.001, \eta^2 = .035$ , Hall = Del&Hall, Hall < Del, Del-Hall and Hall-Dell  $P_s < 0.05$ ); Positive symptoms ( $F_{4,714} = 16.440, P < 0.001, \eta^2 = .035$ , Hall < all groups, Dell < Del-Hall, Del&Hall, Hall-Dell); General symptoms ( $F_{4,688} = 8.085, P < 0.001, \eta^2 = .045$ , Hall < all groups).



**Table S27. NAPLS 3, Total symptom severity, Perceptual Abnormalities (P4), Unusual Thought Content (P1), and Suspiciousness or Persecutory Ideas (P2)**

	Total scores for Scale of Psychosis-risk Symptoms (SOPS)									Perceptual Abnormalities and Hallucinations (P4)							Unusual Thought Content (P1) & Suspiciousness or Persecutory Ideas (P2)								
	BL	2M	4M	6M	8M	12M	18M	24M		BL	2M	4M	6M	8M	12M	18M	24M	BL	2M	4M	6M	8M	12M	18M	24M
	N	105	56	52	51	46	49	38	32	105	75	70	62	57	62	46	41	105	75	70	62	57	62	46	41
Hall-Del	M	38.7	34.3	29.6	28.8	26.1	25.8	23.8	21.6	3.9	3.3	3	2.8	2.5	2.4	2	1.8	4	3.4	3.2	3	2.8	2.8	2.4	2.2
	SD	12.1	12.3	13.9	14.3	12.6	13.1	13.3	11.7	0.7	1.2	1.5	1.5	1.6	1.5	1.6	1.5	0.6	1.2	1.5	1.2	1.4	1.4	1.6	1.5
	N	153	84	71	72	73	65	55	48	154	103	85	86	86	77	65	58	154	103	85	86	86	77	65	58
Del - Hall	M	41.5	37.9	36.4	32	31.1	29.5	28.7	28.5	3.7	3.1	2.8	2.7	2.3	1.8	1.7	1.6	4.3	3.8	3.6	3.2	3.1	2.9	2.7	2.7
	SD	12.1	12.3	13.7	14.1	14.5	14.2	13.6	14.5	0.7	1.3	1.5	1.4	1.4	1.4	1.4	1.3	0.6	1	1.2	1.3	1.3	1.2	1.3	1.2
	N	236	129	128	111	111	96	85	75	240	163	151	129	135	115	97	85	240	163	151	129	135	115	97	85
Del & Hall	M	40.4	35.5	33.1	32.9	29.4	27.6	24.8	26.3	3.8	3.3	2.9	2.6	2.5	2.2	2.1	2	4.2	3.8	3.6	3.2	3	2.8	2.5	2.5
	SD	12.7	13.7	14.3	14.9	16.6	15	15	15.3	0.7	1.2	1.5	1.6	1.7	1.6	1.5	1.6	0.7	1	1.2	1.4	1.5	1.5	1.5	1.5
	N	177	95	82	81	79	75	60	42	179	123	112	102	103	97	71	51	179	123	112	102	103	97	71	51
Del	M	38.8	34.4	33.3	29.2	29.7	28	26.9	23.6	1.2	1.2	1.1	1.1	1.2	1.1	1.1	0.8	4.1	3.4	3.1	2.9	2.7	2.6	2.5	2.3
	SD	13	14.9	14.9	14.1	13.7	16.7	15.3	14	0.9	1.2	1.2	1.3	1.3	1.3	1.2	1	0.7	1.2	1.3	1.4	1.4	1.5	1.5	1.5
	N	16	1	2	2	1	2	0	0	21	19	17	17	16	16	9	9	21	19	17	17	16	16	9	9
Hall	M	24.4	12	15	10	9	15.5	0	0	4	3.5	2.8	2.9	2.6	2.4	2.7	1.8	1.6	1.6	1.4	1.2	1.4	1.7	1.7	1.1
	SD	11.5	0	8.5	0	0	2.1	0	0	0.6	1	1.5	1.5	1.2	1.6	1.6	1.6	0.5	0.8	0.9	1	1.2	1.6	1.7	1.3

Note. Hall-Dell = participants who reported retrospectively having hallucinations as first symptom and then developed delusions; Dell-Hall = participants who reported retrospectively having delusions as first symptom and then developed hallucinations; Del&Hall = participants who reported delusions and hallucinations at the same onset; Del = participants that reported delusions as a first symptom; Hall = participants who reported hallucinations as a first symptom.

**Table S28. NAPLS 3, Disorganized, Negative, and Positive Symptoms.**

	SOPS Disorganized Symptoms			SOPS Negative Symptoms			SOPS Positive Symptoms			SOPS General Symptoms		
	N	M	SD	N	M	SD	N	M	SD	N	M	SD
Hall-Del	105	4.94	2.905	105	10.91	5.908	105	13.13	3.01	105	9.71	4.12
Del-Hall	153	4.91	3.042	154	12.94	6.179	154	14.05	2.846	153	9.65	4.156
Del&Hall	237	5.26	3.084	236	11.61	6.08	240	13.74	3.241	236	9.84	4.298
Hall	16	2.44	1.75	16	7.81	6.102	21	7.86	2.535	16	6.06	4.234
Del	177	5.59	3.367	177	12.94	6.562	179	11.44	3.248	177	8.8	4.161
Total	688	5.15	3.132	688	12.05	6.272	699	12.95	3.384	687	9.42	4.244

Note. Hall-Del = participants who reported retrospectively having hallucinations as first symptom and then developed delusions; Del-Hall = participants who reported retrospectively having delusions as first symptom and then developed hallucinations; Del&Hall = participants who reported delusions and hallucinations at the same onset; Del = participants that reported delusions as a first symptom; Hall = participants who reported hallucinations as first symptoms. Disorganized symptoms ( $F_{4,689} = 4.360$ ,  $P = 0.002$ ,  $\eta^2 = .025$ , Hall < all groups,  $P_s < 0.05$ ); Negative symptoms ( $F_{4,683} = 4.748$ ,  $P < 0.001$ ,  $\eta^2 = .027$ , Hall < Del-Hall and Del,  $P_s < 0.05$ ); Positive symptoms ( $F_{4,694} = 33.528$ ,  $P < 0.001$ ,  $\eta^2 = .162$ , Hall < all groups, Del < Del-Hall, Del&Hall, Hall-Del,  $P_s < 0.05$ ); General symptoms ( $F_{4,714} = 4.365$ ,  $P = 0.002$ ,  $\eta^2 = .025$ , Hall < all groups, Del < Del-Hall).



**Table S29. Presence prior to prodrome and course of Delusion and Hallucination-Spectrum symptoms based on the TOPE**


	Odd/Bizarre Ideas (n = 431)	Suspiciousness/ ideas of reference (n = 431)	Delusions (n = 343)	Unusual Perceptual Experiences (n = 434)	Hallucination (n = 344)
Ever experienced prior to psychosis onset?	131 (30.4%)	168 (39%)	16 (4.7%)	78 (18%)	18 (5.2%)
	Course (n= 389)	Course (n = 386)	Course (n = 11)	Course (n = 406)	Course (n = 14)
Not present during prodrome	176 (45.2%)	97 (25.1%)	Missing	218 (53.7%)	Missing
Present during one phase	20 (5.1%)	28 (7.3%)	8 (72.7%)	14 (3.4%)	7 (50%)
Present during several phases	14 (3.6%)	28 (7.3%)	1 (9.1%)	18 (4.4%)	6 (42.9%)
Persistent	54 (13.9%)	81 (21%)	None	30 (7.4%)	None
Lifelong pattern of behavior	11 (2.8%)	7 (1.8%)	None	3 (0.7%)	None
Uncertain	18 (4.6%)	13 (3.4%)	2 (18.2%)	23 (5.7%)	1 (7.1%)
Only after psychosis onset	96 (24.7%)	132 (34.2%)	Missing	100 (24.6%)	Missing

## References


1. McGlashan T, Walsh B, Woods S. *The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-Up*. Oxford University Press; 2010.
2. Rosengard RJ, Malla A, Mustafa S, et al. Association of Pre-onset Subthreshold Psychotic Symptoms With Longitudinal Outcomes During Treatment of a First Episode of Psychosis. *JAMA Psychiatry*. Published online 2018. doi:10.1001/jamapsychiatry.2018.2552
3. Shah JL, Crawford A, Mustafa SS, Iyer SN, Joobar R, Malla AK. Is the Clinical High-Risk State a Valid Concept? Retrospective Examination in a First-Episode Psychosis Sample. *Psychiatric Services*. 2017;68(10):1046-1052. doi:10.1176/appi.ps.201600304
4. Addington J, Liu L, Buchy L, et al. North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms. *J Nerv Ment Dis*. 2015;203(5):328-335.
5. Addington J, Liu L, Brummitt K, et al. North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description. *Schizophr Res*. 2022;243:262-267.
6. Miller TJ, McGlashan TH, Woods SW, et al. Symptom assessment in schizophrenic prodromal states. *Psychiatr Q*. 1999;70(4):273-287.
7. Krabbendam L, Myin-Germeys I, Hanssen M, et al. Hallucinatory experiences and onset of psychotic disorder: evidence that the risk is mediated by delusion formation. *Acta Psychiatr Scand*. 2004;110(4):264-272.
8. Zhang T, Xu L, Tang Y, et al. Isolated hallucination is less predictive than thought disorder in psychosis: Insight from a longitudinal study in a clinical population at high risk for psychosis. *Sci Rep*. 2018;8(1):13962.
9. Niles HF, Walsh BC, Woods SW, Powers AR 3rd. Does hallucination perceptual modality impact psychosis risk? *Acta Psychiatr Scand*. 2019;140(4):360-370.
10. Cannon TD, Yu C, Addington J, et al. An individualized risk calculator for research in prodromal psychosis. *Am J Psychiatry*. 2016;173(10):980-988.
11. Azis M, Rouhakhtar PR, Schiffman JE, Ellman LM, Strauss GP, Mittal VA. Structure of positive psychotic symptoms in individuals at clinical high risk for psychosis. *Early Interv Psychiatry*. 2021;15(3):505-512.
12. Hawkins KA, McGlashan TH, Quinlan D, et al. Factorial structure of the Scale of Prodromal Symptoms. *Schizophr Res*. 2004;68(2-3):339-347.
13. Payne J, Malla A, Norman R, Windell D, Brown N. Status of First-Episode Psychosis Patients Presenting for Routine Care in a Defined Catchment Area. *The Canadian Journal of Psychiatry*. 2006;51(1):42-47. doi:10.1177/070674370605100108
14. Andreasen NC. *Scale for the Assessment of Positive Symptoms: SAPS*.; 1984.
15. Alonso J, Ciudad A, Casado A, Gilaberte I. Measuring schizophrenia remission in clinical practice. *Can J Psychiatry*. 2008;53(3):202-206.
16. Paquin V, Malla AK, Iyer SN, Lepage M, Joobar R, Shah JL. Combinations and Temporal

Associations Among Precursor Symptoms Before a First Episode of Psychosis. *Schizophr Bull.*  
Published online October 20, 2023. doi:10.1093/schbul/sbad152


17. Paquin V, Cupo L, Malla AK, Iyer SN, Joobar R, Shah JL. Dynamic association of the first identifiable symptom with rapidity of progression to first-episode psychosis. *Psychol Med.* 2023;53(5):2008-2016.



**Supplemental Figure S1. Combined NAPLS 2 and 3 symptom onset trajectories, split by remission status.** In both participants whose symptoms remitted (left) and those whose symptoms persisted or got worse over time (right), hallucination onset was preceded by a period of elevated delusional intensity. After hallucination onset, both remitters and non-remitters demonstrated a decrease in hallucination and delusion intensity. Red = hallucinations; blue = delusions.



**Supplemental Figure S2. Full transition matrices** from symptom states ( $y$ ) to immediately subsequent symptom states across all three samples. Comparisons reported in **Table S21**.



**Supplemental Figure S3. Symptom severity in NAPLS 2, NAPLS 3, and PEPP samples.** Mean scores for P4, P1, and P2 over time are presented, with sample selection criteria identical to the LZC analysis. Error bars = 1 SEM.